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Four studies were carried out in the present thesis. In the first study 65 poultry chickens were 
randomly divided into 4 groups: group A (n = 20) and B (n = 20) received the drug orally (PO), in 
group C (n = 20) the drug was injected by intravenous (IV) route, whereas group D (n = 5) was 
the control group. The analysis of plasma samples and residues in organs were performed through 
the HPLC-FL instrument. The second study was divided into 2 phases where at the same 6 lactating 
goats were given tulathromycin drug before gestation and during lactation postpartum period. In 
the first phase of the study, tulathromycin was administered at 2.5 mg/kg b.w. by IV and 
subcutaneous (SC) routes. In the second phase of the study, the same animals were administered 
with a single IV dose. The analysis of plasma samples and organs were performed through the 
HPLC-MS/MS instrument. In the third study, 20 laying hens were divided into 3 groups: group A 
(n=6), B (n=6) and C (n=8). During the first phase group A and B was administered the drug 
tapentadol by IV and PO routes at the dose of 1 and 5 mg/kg b.w. respectively. In the second phase 
of study, group C received the drug by PO at a dose of 5 mg/kg b.w. for 5 consecutive days. The 
eggs were collected for 30 days from the beginning of the experiment. Plasma, egg yolk and album 
samples were analysed using the HPLC-FL instrument. In the fourth study, 6 lactating goats were 
divided into 2 groups: group A (n = 3) and B (n = 3) where meloxicam was administered by IV 
and intramuscular (IM) routes at a dose of 0.5 mg/kg b.w. Milk samples were taken up to 168 h 
for quantification of drug residues in the organic matrix. The plasma and milk samples were 
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Over the last decades, animal production science supported the modernization of food animal 
husbandry in order to provide adequate food supply to meet the demands of a growing population. 
Food producing animals bred in optimized conditions supply a large amount of food derivatives 
(milk, eggs, meat, honey and fish) and produce foodstuffs that are safe for the human consumption. 
Furthermore, in the recent years, society has become progressively more concerned about food 
producing animals suffering and aware of the need of disease prevention and treatments. The use 
of veterinary drugs are necessary to meet the challenges of providing adequate amount of food but 
also to prevent and treat food producing animals diseases. However, this is not obtained without 
the risk for human health associated with drugs residues that remain in the tissues of treated 
animals at the time of slaughter or residues in animal derived products (De Vito, 2015; Giorgi et 
al., 2016; Beyene, 2016).  
In the United States of America (USA), the Food and Drug Administration (FDA) is the regulatory 
body that sets maximum permitted concentrations for veterinary drug residues, known as 
tolerances. In the European Union (EU), the equivalent regulatory body is the European Medicines 
Agency (EMA), which publishes maximum residue limits (MRLs) of the selected marker residue 
that have been set by the Committee for Medicinal Products for Veterinary Use (CVMP) (Baynes 
et al., 2016). The marker residue is usually the parent drug but can be a drug metabolite or the total 
concentration of several metabolites (Lees & Toutain, 2012). In CVMP position paper is reported 
that “substances capable of pharmacological action are substances which are 
pharmacodynamically active at the dose at which they are administered to the target animal by 
means of the veterinary medicinal product in which they are included”. While, residues are 
“pharmacologically active substances  which remain in foodstuffs obtained from animals to which 
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1.1 The risk analysis framework 
During the past 30 years, a risk analysis framework for food safety has been developed. It 
comprises three major elements: risk assessment, management and risk communication. 
1.1.1 Risk Assessment 
The assessment of dietary risk is  conceptualized in the present  equation (Eq. 1):  
 
Eq. 1     Risk = Hazard x Exposure 
 
Where, “risk” is the probability of harm occurring to the consumer; “hazard” refers to the chemical 
residue representing a source of potential harm attributable to its intrinsic properties; “exposure” 
refers to the dietary exposure to the chemical residue. 
It is important to underline that the above relationship highlights a fundamental difference between 
“hazard” and “risk”: 
“Hazard is the inherent property of an agent or situation having the potential to cause adverse 
effects when an organism, system, or (sub) population is exposed.”  
“Risk is the probability of an adverse effect in an organism, system, or (sub) population caused 
under specified circumstances by exposure to an agent.” 
Under the normal physiological conditions, following drug administration, most of the drugs are 
metabolized in order to facilitate the elimination. The parental drug and its metabolites are excreted 
in urine and a lesser extent via faeces. However, these substances may also be found in milk, eggs 
and meat (Beyene, 2016). Indeed, established MRLs information are needed relating to how each 
drug product is to be used. It includes the recommended dose and frequency of administration and 
application, pharmacokinetic and metabolic studies in experimental and food producing animals, 
residue depletion studies with radiolabelled drugs in target animals, a description of analytical 
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designed to assess the impact of residues of antimicrobial agents on food processing (Reeves, 
2010). When residue levels exceed, the MRLs values consumer could develop adverse health 
effects. Potential adverse health effects can include allergic reactions, immune-depressive effects, 
blood dyscrasias, mutagenic effects, carcinogenicity, teratogenic effects and cardiovascular 
toxicity (Nebbia, 2009). Differently, residue levels that are below the MRLs are considered safe 
when food at that level is consumed daily for a lifetime. 
Derivation of the MRLs requires algorithms and several toxicological, pharmacological, and 
microbiological data packages. The risk assessment process is a standard battery of safety studies 
in animals and humans as well as in vitro studies that are used to determine the acceptable daily 
intake (ADI). The resulting toxicological ADI is often determined from the lowest no-observable-
adverse-effect level (NOAEL) and lowest-observable-adverse-effect level (LOAEL) obtained 
from the animal and human studies. These NOAELs and LOAELs are often adjusted by 
uncertainty factors to account for species differences (10 for animal to human extrapolations 
respectively) and intra-species differences (10 for variability within a population). The ADI is then 
adjusted with food consumption values for various organic matrices (300 g for muscle, 100 g for 
liver, 50 g for kidney, 50 g for fat, and if a dairy approval,1500 g for milk) to obtain MRLs for 
each matrix (Table 1). This requires kinetic data for each matrix, to be sure that the total food 
basket of residues at each matrix results in less than the ADI. (EMA/CVMP/SWP/355689/2006; 
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Table 1. Values of ADI (gr or mL) for the MRL evaluations (EMA/CVMP/SWP/355689/2006) 
Mammals Birds Fish 
Muscle 300 Muscle 300 Muscle+Skin 300 
Fat 50 Fat+Skin 90   
Liver 100 Liver 100 Bee 
Kidney 50 Kidney 10 Honey 20 
Milk 1500 Eggs 100   
 
 
1.1.2 Risk management 
Good practice in the use of veterinary drugs is defined as the official recommended or authorised 
usage, including withdrawal periods, approved by national authorities (Codex Alimentary  
Commission Procedural Manual, 18th edition, 2008). The withdrawal period (also referred to as 
withdrawal time or withholding period) is the interval between the time of the last administration 
of a veterinary drug and the time when the animal can be safely slaughtered for food, or collected 
milk and eggs safely for the human consumption. Compliance with the withdrawal period provides 
an high degree of assurance to both producers and consumers that the concentration of residues in 
foods derived from treated animals will not exceed the MRLs. Withdrawal periods are typically 
assigned on the basis of results of a residue depletion study using non-radiolabelled drug in which 
the veterinary drug product proposed for marketing is administered at the highest label rate, the 
shortest dosing interval and for the longest duration. These conditions represent a worst-case 
scenario for residue depletion (Reeves, 2010). 
1.1.3 Risk communication 
Evaluation reports are necessary to document the risks and the proposed approaches to manage the 
identified risks. Based on these reports and dialogue with the risk assessors, risk managers gain a 
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assessment, and the implications of the proposed strategy for managing the risks. The regulator 
must ensure that producer organizations and consumers understand the identified risks and the 
proposed risk mitigation strategy. Consumer engagement, including the presentation of 
programmes that provide an understanding of the regulatory processes, serves to assure consumers 
that drug residues in animal derived foods do not pose a health risk (Reeves, 2010).  
 
1.2 Major and minor animal species in veterinary medicine 
One of the most important challenge of veterinary medicine is the necessity to treat many types of 
animals including livestock, companion animals, working animals, sport animals, laboratory 
animals etc. This leads to the necessity of a rational dosing regimen of each species influenced by 
anatomy, biochemistry, physiology and behaviour of a given species. Moreover, some species 
show considerable differences within and between breeds in pharmacokinetic (PK) and 
pharmacodynamic (PD) profiles (Toutain et al., 2010). 
Concerning livestock species, nowadays it has been identified more than 40 domestic species. The 
World Watch List for Domestic Animal Diversity (WWL-DAD:3) issued by FAO (2000) provides 
inventories of the species and breeds of the domestic animals used for food production. Thirteen 
species contribute to most of the world’s food and agricultural production and are considered of 
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For these reasons, some species are classified as major and others as minor species by the 
regulatory agencies in Europe and the US (Table 2). 
 
Table 2. Major and minor food producing species (EMEA/CVMP 2003) 


















1.2.1 Off-label drugs and dosage regimens 
Veterinary pharmacology still presents a reduced drug armamentarium for both major and minor 
animal species. Off-label drugs represent an opportunity to treat more and more new categories of 
disease. They refer to the use of an approved drug in a manner that is not in accordance with the 
approved label directions; they occur when a drug, only approved in human medicine, is used in 
animals; when a drug, approved for one species of animal, is used in another one; when a drug is 
used to treat a condition for which it was not approved, or the use of drugs at levels in excess of 
recommended dosages. Off-label drugs in food-producing animals present particular conditions. 
The veterinarian may not use an approved human drug if an animal drug approved for use in food-
producing animals can be used. Finally, if scientific information on the human food safety aspect 
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appropriate measures to assure that the animal and its food products will not enter the human food 
supply (Beyene, 2016).  
It is clear that the lack of new innovative therapies in veterinary medicine and the multiplicity of 
species of veterinary interest with their large interspecies differences in PK and PD profile requires 
some modelling tools to extrapolate PK and PD parameters between species. Allometric scaling is 
one of these approaches based on the influence of physiological properties of body size, 
metabolism and PK data ; on the contrary, PD data are considered negligible. It is a useful method 
to provide a first estimation of a dosage regimen, but it is predictive only if the differences between 
animal species are qualitative rather than quantitative. Especially for some minor species, excluded 
from the major drug companies that do not wish to grant a local marketing authorization, it is 
possible to extrapolate the dose from major species thanks to PK data. It consists to scale the 
approved dose in the major species against ratio of clearance of the two species in question (Eq.2) 
(Toutain & Bousquet-Melou, 2009): 
 
Eq. 2   Dose new specie = Dose reference specie x 
Clearance new specie
Clearance reference specie 
 
 
Another approach to determine the optimal dosage regimens are PK/PD studies which calculate 
the effective dose (Eq 3.): 
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Where “ED” is an efficacious dose, “Cl” is the plasma (total) clearance, bioavailability is referred 
to a particular route of administration and “EC” is the efficacious plasma concentration. This 
approach can predict the optimal rational dose, but also predicts the rate of depletion of residues 
from foods derivate (Toutain et al., 2010). 
1.2.2 Species variabilities in poultry 
Although, some poultry species such as chicken and turkey are considered as a major food-
producing animals, PK and PD variability among poultry species (major and minor species) is 
large enough to consider that each species must be treated in its own right.  
Taking in consideration the poultry medications, most of the drugs approved or given in off-label 
manner to these animal species are administered orally (90% of all treatments). To achieve an 
effective collective treatment in poultry, special attention must be given to poultry feeding and 
drinking behaviours and to the species characteristics of digestive tract physiology. Drinking water 
is the preferred mode of drug administration, especially for antibiotics, because diseased birds tend 
to stop eating but usually continue to drink. The alternative to the drinking administration is the 
added of drug in food by a pre-mix formulation. On the other hand, additional biological 
information such as  body weight, age, and gender, but also environmental (lighting period and 
temperature) and managerial factor such as the composition of the diet, are necessary to determine 
an appropriate dosage regimen and to predict the rate of depletion of residues from meat and eggs 
(Toutain et al., 2010). 
1.2.2.1 Drug residues in eggs. 
Figure 2 show the anatomy of the avian eggs. Eggs are constituted by three mainly components: 
yolk, albumen, and shell. Yolk has the longest development time. Precursors to yolk lipoproteins 
are produced in the liver and transported through circulation to the yolk follicles in the ovary. In 
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the ovary. Before an egg is laid, the yolk undergoes a stage of rapid growth, in which it increases 
in size exponentially over 10 days. Drugs that deposit in the yolk are rapidly accumulate during 
this time and can be present in successive eggs for 10 or more days following treatment. Following 
yolk maturation, the albumen is laid down over a period of 2-3 h and can also serve as a residue 
accumulation site. The egg shell is added, after that albumen proteins are deposited and diluted 
with water. The egg development process is similar across species of poultry and game birds, 
although the rates of development vary (Montesissa & Nebbia, 2009; Goetting et al., 2011).  
 
 
Figure 2. Illustration of egg anatomy 
 
Concerning drug residues, many drugs deposit preferentially in the yolk or albumen, depending 
on the drug’s physicochemical properties. Some characteristics that affect the distribution of 
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the ability to move through different tissue types. However, a drug’s kinetic properties cannot 
always be predicted from its chemical properties (Montesissa & Nebbia, 2009; Goetting et al., 
2011). 
1.2.3 Species variabilities in caprine 
As previously observed in Table 2 caprine are considered as minor species, though domestic goat 
(Capra aegagrus hircus) has many characteristics that make it a valuable livestock species. First 
of all, goats can survive on range land and plant species that other ruminants cannot. According to 
the Food and Agriculture Organization of the United Nations, over 90% of the world's goats are 
in developing countries with world’s goat population over 861,000,000 head (Clothier, 2010). 
Actually, this animal species is considered as a minor species by the regulatory agencies in Europe 
and USA, but goats present a worldwide population large enough to confer a status of major 
species (Toutain et al., 2010). Indeed, while goats represent a growing segment of agriculture, 
their numbers are far lower than those of other livestock species and many of their health issues 
cannot be addressed with EMA or FDA-approved medications (Clothier, 2010). Consequently, 
many drugs are administered to goats in an extra-label manner with no scientific information on 
drug behaviour, with a potential toxicity and with an inadequate withdrawal periods for drug 
removal from products marketed for human consumption. 
Goats have many unique differences in anatomy, physiology and product biochemistry, from sheep 
and cattle which support the contention of many unique qualities of dairy goat products for human 
nutrition. Goat milk and its products of yogurt, cheese and milk-powder have three-fold 
significance in human nutrition:  
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• Treating people afflicted with cow milk allergies and gastro-intestinal disorders, which is a 
significant segment in many populations of developed countries. 
• Filling the gastronomic needs of consumers, which is a growing market share in many 
developed countries. 
The physiological and biochemical facts of the unique qualities of goat milk are just barely known. 
The high levels in goat milk of short and medium chain fatty acids have recognized medical values 
for many disorders and diseases of people. Moreover, the enrichment of short and medium chain 
fatty acids in goat butter, and their greater concentration compared to cow butter, could have 
become a valued consumer item supporting the idea of promoting goat butter (Haenlein, 2004). 
Species differences in drug action and effect reflect differences in target functions (anatomy, 
physiology, pathology) and/or target receptors (Toutain et al., 2010). For example, goats are 
frequently used as models for studying respiratory disease in cattle due to the similarity of these 
two species in susceptibility to inciting causes, bacterial pathogens, and mechanisms of pathology 
but differences in serotype, capsular type, and species of recovered bacteria (Clothier, 2010). 
Moreover, goats have generally a more active metabolism than sheep or cattle. This is linked to 
their respective feeding behaviour where goats are natural browsers that can stand on their hind 
legs or even climb trees. They preferably eat leaves, shrubs, flowers and fruits, thus choosing the 
most nutritious available food but also the portions of plants containing many toxic alkaloids that 
need to be metabolised by a hepatic first pass effect. In contrast, cattle are a non-selective bulk 
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1.3 Pharmacokinetics and drug residues 
Pharmacokinetics is the science that describes quantitative changes in drug concentration in the 
body over time as a function of administered dose. It is usually based on subjecting serum/plasma 
concentration-time data to mathematical models in order to determine quantitative terms, which 
describe absorption, distribution, metabolism, and excretion of the drug and its metabolites. 
Residue depletion profiles are linked to administered doses of drugs through their pharmacokinetic 
profiles (Lees & Toutain, 2012).  
Several fundamental parameters are critical to establishing valid models from which other 
parameters can be determined. Clearance (Cl), is the amount of drug removed per unit of time; it 
is the most important parameter to determine since it dictates the dose and frequency of drug 
administration needed to reach a steady-state concentration. The volume of distribution (Vd) 
dictates how broadly the drug mobilizes throughout the body and is proportional to the amount of 
drug in the body; it is generally small if most of the drug is retained in the blood stream and large 
if the drug disseminates to tissues. Bioavailability (F%) is the percentage of drug that will reach 
the intended destination, which is generally the blood stream. Physiochemical traits of a drug such 
as size, lipid solubility, degree of ionization, and protein binding properties determine how it will 
traverse cell membranes and arrive at a target location, how it will persist at that location, and how 
it will be removed from that location. F% is considered complete for drugs administered 
intravenously, but must be determined for those administered by other routes (intramuscular, 
subcutaneous and oral routes). In this case, F% will influence Vd and Cl; consequently, they will 
become apparent clearance (CL/F) and apparent volume of distribution (Vd/F). Moreover, the area 
under the time-concentration curve (AUC) gives an estimation of total drug exposure. Half-life 
(t½) is the time needed to remove half of the drug from the compartment under study (usually 
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elimination rate of a drug is estimated by the determining the terminal slope (λz) of the time-
concentration curve. Finally, the maximum drug concentration (Cmax) and time to reach maximum 
drug concentration (Tmax) are derived directly from the time-drug concentration plot (Bauer, 2004; 
Gabrielsson & Weiner, 2000; Goodman & Gilman, 2006; Rescigno, 2003). 
Pharmacokinetic analysis is used to estimate parameters that characterize the behaviour of a drug 
and can be done experimentally or through the use of modelling. Pharmacokinetic modelling 
attempts to match drug behaviour with mathematical equations that can be used to predict drug 
activity in other populations. Non-compartmental PK models of experimental results consider the 
entire body as a single “vessel” into which the drug is administered and from which the drug is 
removed. These models make the fewest assumptions about how the drug is distributed without 
the need to describe movement from one location to another. On the contrary, compartmental 
analysis uses kinetic models to predict the time-concentration plot and considers drug entry and 
elimination from various segments of the body, such as blood, fat, or central nervous system 
(Bauer, 2004; Gabrielsson & Weiner, 2000; Goodman & Gilman, 2006; Rescigno, 2003). 
Anti-microbial and anti-inflammatory drugs are used extensively in farm animal species for 
prophylaxis (administration to prevent disease), metaphylaxis (treatment of animals not showing 
clinical signs of disease but in contact with those which are), and therapy (treatment of animals 
displaying clinical signs of disease). For regulatory purposes, pharmacokinetic profiles are 
established in healthy animals; small numbers of animals, usually of a single breed, of similar age, 
and possibly of the same gender are used with an intensive sampling schedule (Lees & Toutain, 
2012). However, it is clear that the PK behaviour is influenced by chemistry properties of the drug, 
dose, route of administration, but also age, gender and pathological conditions and the animals of 
interest. The absorption and distribution processes, the bioavailability of the drug and its 
metabolites in different organs and tissues and finally the elimination and depletion of the drug are 
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organic matrices used for the production of foodstuffs (Montesissa, 2009). Moreover, 
concentrations of veterinary drug residues depend on a range of properties such as lipid solubility 
and acidic/basic characteristics, which influence the passive diffusion of drugs across cell 
membranes. High lipid solubility drugs (for example fluoroquinolones and macrolides) cross cell 
membranes readily by passive diffusion to penetrate into intra- as well as extracellular 
compartments of tissues. Moderate to high lipid solubility drugs, similarly, generally enter readily 
into all water compartments of tissues. On the other hand, drugs of low lipophilicity generally do 
not readily enter cells, so that these drugs are located mainly or solely in the extracellular 
compartment of tissues. Concerning the acid/base characteristics of the molecule, take in 
consideration that intracellular fluid pH is lower than extracellular fluid pH (7.0 versus 7.4), weak 
bases penetrate readily into cells, by the classical Henderson-Hasselbalch mechanism of 
ion/diffusion trapping, whereas weak acids do not.  
The CVMP (CE n. 2377/90) has issued specific guidelines for pharmacokinetics studies and 
residues depletion to define the behaviour of the different drugs in animal species and to establish 
rules of experimental design. All these information are needed to establish a maximum residue 
tolerable to ensure safety to the consumers in a day-to-day exposure condition and to harmonized 
the MRLs of the different countries of EU to a maximum required performance limit of the 
analytical methods (Montesissa, 2009). The concept “zero tolerance” is equivalent to the idea of 
total absence of residual amounts. Obviously, because of the improvement of analytical 
techniques, the value of zero becomes smaller and smaller that depicts the limits corresponding to 
the sensitivities of part per million (ppm), part per billion (ppb) and part per trillion (ppt). As a 
result, by using the high efficacy analytical methods such us the high performance liquid 
chromatography, it can be concluded that there are nearly always detectable residues but an 
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1.4 Analytical methods 
The analytical methods for the determination of residues in different matrices are conventionally 
subdivided in 3 levels: 
- The third level provides qualitative information. These level represent the screening method used 
to determine the presence/absence of drug to a concentration of interest. These methods are 
characterized by a high productivity, low cost, ease of use and not high technologies. An example 
of analytical method that belongs to this level is the test ELISA. 
- The second level provides quantitative information. The analytical methods that belong to this 
level are confirmatory tests. These methods are characterized by a high technology, validation of 
methods and preparation of samples depending to the chemistry properties. Example of the present 
method is the high performance liquid chromatography (HPLC) with different detector 
(ultraviolet, spectrofluorometric and diode array detectors) 
- The first level provides information with elevate significance. The analytical methods that belong 
to this level are confirmatory test. Example of analytical methods are gas chromatography and 
liquid chromatography with mass spectrometry detector (GC-MS/MS and LC-MS/MS) 
(Nachtmann, 2009). 
The analytical methods utilized in the present thesis are: 
- High performance liquid chromatography with spectrofluorometric detector (HPLC-FL) and 
diode array (HPLC-DAD). The spectrofluorometric detector, is used to determine fluorescent 
substances by a chromatographic curve obtained recording a signal at a specific emission and 
excitation wavelengths. The diode array detector allows to scan simultaneously at discrete 
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-Liquid chromatography mass spectrometry (LC-MS/MS). The mass spectrometry detector is able 
to provide information on the structure of the molecule under examination on the basis of the 
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2. Chemical and pharmacological properties of drugs of interest 
 
2.1 Antibiotic drugs 
As mentioned in chapter 1, it’s necessary to have greater knowledge of the pharmacokinetics of 
drugs in different animal species, but also are needed more information about the biological and 
toxic effects induced by these molecules in both the animal and human (Odore & Badino, 2009). 
Pharmacodynamics is the study of the relationship between drug exposure and the biological 
effects of  the drug on the host or, in the case of an antibiotic, on the bacterial target.  
Parameters used to evaluate PD effects of antibiotics include the minimum inhibitory 
concentration (MIC) against specific bacterium in vitro, the post-antibiotic effects (PAE) and 
kinetics of bacterial killing (Figure 3) (Gabrielsson & Weiner, 2000; Rescigno, 2010; Godinho et 
al., 2005; Wise, 2001).  
The MIC is defined as the lowest concentration of antimicrobial that suppresses bacterial growth 
in a defined incubation period (Catry et al., 2007). The MIC determination involves an incubation 
of a bacterial suspension with a range of doubling antibiotic concentrations for a specified time 
and how their growth is inhibited. The MIC is considered the “gold standard” of susceptibility test. 
Depending on the quantitative antimicrobial susceptibility as indicated by the MIC value, bacteria, 
in relationship with the drug, are categorized into “clinically susceptible (S),” “intermediate (I),” 
or “resistant (R)” (Mouton et al., 2012). Moreover, the mean bactericidal concentration (MBC) 
can be identified by sub-culturing the bacterial antibiotic suspension used in MIC testing onto 
antibiotic-free media to determine what concentration of antibiotic is required for a complete 
bacterial killing. Bactericidal antibiotics have MBC that are very close to MIC values, since their 
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are much greater than MIC. Kill-kinetic assays are an established method to determine the degree 
of bacterial killing. The most common chosen levels of killing are MBC90 (90% killed), MBC95 
(95% killed), and MBC99 (99% killed) (Andrews, 2001; Firsov et al., 1997; Stratton et al., 1987). 
 
 
Figure 3. PK and PD parameters 
 
Antibiotics are traditionally classified into each one of the following three categories: time-
dependent, concentration-dependent, and time-dependent with a post-antibiotic effect, based on 
PK/PD activity (Figure 3 and 4). The activity of time-dependent antimicrobials relies on the length 
of time that drug levels are at or above the MIC (T>MIC) of the specific pathogen being treated. 
More the drug levels persist above the MIC, more effective is the antibiotic treatment. Common 
time-dependent antibiotics include penicillins, cephalosporins, and older macrolides. 
Concentration-dependent antimicrobials depend on the maximum level of antimicrobial above the 
MIC (Cmax/MIC) of the pathogen being treated. An effective treatment is based upon maximizing 
plasma or tissue concentrations of the drug and benefits from the suppression of bacterial growth 
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tetracyclines, and fluoroquinolones are members of this category. The concentration-effect 
relationship is empirically described by the sigmoidal Emax model (Hill equation Eq. 4): 
 





Where “E(t)” is the effect observed for a given concentration (C) at time (t). “Emax” is the maximal 
effect attributable to the drug. “EC50” is the plasma concentration producing 50% of Emax; “H” is 
the Hill coefficient which describes the steepness of the sigmoidal relationship between the  
concentration and the effect. “E0” is the rate of background response in the absence of drug (such 
us that achieved by the host immune response) (McKellar et al., 2004; Martinez et al., 2013).  
The third category of antibiotics, which includes streptogramins, ketolides, and newer macrolides, 
has characteristics of both, with time-dependent killing mechanisms and PAE. PAE is based on 
the concentration of drug, the time that bacteria is in contact with the drug, and its mechanism of 
action. Total drug exposure is evaluated by the area under the time-concentration curve (AUC) 
and represents a mathematical summation of drug concentrations in the compartment being 
assessed. The AUC/MIC ratio is frequently used to determine the drug efficacy (Toutain et al., 
2002; Martinez et al., 2013; McKellar et al., 2004; Van Bambeke & Tulkens, 2001; Gabrielsson 
& Weiner, 2000; Li & Zhu, 2002). 
The AUC/MIC ratio may be used to compute a dose using the following equation (Eq. 5): 
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where “Dose (per day)” is the daily maintenance dose at steady state; “Cl” is the plasma clearance 
expressed as L/h. “(AUC/MIC)breakpoint” the targeted AUC/MIC value (e.g. 125 h) provides a 
dose achieving an average plasma concentration over 24 h in the steady state equal to 
approximately five times MIC (125h/24h). “MIC90” the 90th percentile of the MIC distribution. 
“fu” (from 0 to 1) the free (unbound) fraction (only the free antibiotic plasma concentration is a 
relevant plasma surrogate of the free antibiotic concentration at the biophase level) and F the 














Figure 4. PK/PD analysis 
 
When PK/PD indexes are not in these values, mutated bacterial strains exhibit resistance, as the 
mutated species typically has MIC values 4 to 8 times higher than the MIC of the Wild type species 
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2.1.1 Quinolones and fluoroquinolones  
 
Figure 5. Fluoroquinolones chemical structure 
 
Quinolones and fluoroquinolones, comprise a large and expanding group of synthetic 
antimicrobial agents. The first drug of this class, nalidixic acid, was discovered in 1962 and was a 
modification of a compound isolated during the production of the anti-malaria drug, chloroquine. 
Its antibacterial spectrum of activity was restricted to the Enterobacteriaceae and, because of 
limitations in absorption and distribution, the drug was effective solely for the treatment of urinary 
tract infections. In the 1980s, the addition both of a fluorine molecule at the 6-position of the basic 
quinolone structure and a piperazine substitution at the 7-position was found to enhance quinolone 
antibacterial activity, gaining effectiveness against Pseudomonas aeruginosa and Gram-positive, 
cocci, and to increase the extent of oral drug absorption and tissue distribution. Products possessing 
this fluorine molecule are known as the fluoroquinolones (Figure 5).  
Fluoroquinolones belongs to the third generation class of quinolones. This class of drugs exhibited 
an increased antibacterial activity against the Enterobacteriaceae and other Gram-negative 
bacteria (such as P. aeruginosa) compared to the first and second generation of quinolones. It had 
some activity against certain Gram-positive cocci. Structural changes associated with the third 
generation increased their oral bioavailability and systemic distribution. Quinolones fitting into 
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marbofloxacin. Likewise, the fourth generation drugs belonging to the quinolones, maintained the 
favourable characteristics of the third generation drugs while exhibit an increase activity against 
Gram-positive bacteria, anaerobes and mycobacteria. These compounds also exhibited excellent 
oral bioavailability, a prolonged terminal elimination half-life, lower central nervous system 
toxicities and exhibit fewer interactions with the cytochrome P450 (CYP 450) system (Ball, 2000). 
Fluoroquinolones are a class of bactericidal drugs and have of a concentration-dependent nature, 
showing a rapid and profound killing over a wide range of concentrations (Martinez et al., 2013). 
Therefore, the action is evaluated by Cmax/MIC ratios greater than 10 and AUC/MIC whose value 
must be between 100 and 125, in order to have a good antibacterial activity and to limit the 
development of peripheral resistances. (Toutain et al., 2002; Wright et al., 2000). 
2.1.1.1 Chemical properties  
Fluoroquinolones are amphoteric molecules weakly soluble in water for the presents of a 
zwitterion form with the carboxylic acid and the basic amine. The pKa values range from 5.5 to 
6.3 for carboxylic acid and 7.6 to 9.3 for amine group. In acid pH condition both groups are 
protonated, while at  a basic pH condition the carboxylic acid is in the form of anion. For this 
reason, the fluoroquinolones tend to be more water-soluble with acid or basic pH, while at 
physiological pH they exhibit minimum water solubility. Finally, fluoroquinolones have a high 
melting point, generally greater than 200 ° C, so the crystallized form is very stable (Papich & 
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2.1.1.2 Structure–activity relationship 
 
Figure 6. Structure–activity relationship of fluoroquinolones 
 
Figure 6 shows the general structure-activity relationship of the fluoroquinolones. The carboxyl 
group in position 3 and the ketone at position 4 are essential for antibacterial activity. Fluoride in 
position 6 gives a wider spectrum action, a greater power, a greater input capacity in the bacterial 
cell. The N substitution in position 1 with an ethyl, cyclopropyl, fluorophenyl, leads to a wider 
spectrum of action. Substitution at position 7, with a piperazine, increases antibacterial activity 
against Pseudomonas. At position 8, it is preferable to have carbon instead of nitrogen to limit side 
effects at the central nervous system level and increase activity against staphylococci, while 
substitutions with a methoxy or cyan group, in this position, can increase the activity against 
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2.1.1.3 Mechanism of action 
 
Figure 7. Fluoroquinolones mechanism of action 
 
Figure 7 shows the fluoroquinolones mechanism of action. Fluoroquinolones damage bacterial 
DNA and lead to defects in negative supercoiling. This effect was linked to inhibition of DNA 
gyrase activity, an enzyme found in all bacteria. In concert with other proteins, gyrase catalyzes 
changes in the degree of double-stranded DNA supercoiling. In this capacity, it plays a vital role 
in DNA packing, replication and transcription.  
The effect of fluoroquinolones on bacterial proliferation suggests three mechanisms of cell killing:  
1. Mechanism A: common to all quinolones. This requires RNA and protein synthesis and is only 
effective against dividing bacteria. Mechanism A appears to involve the blocking of replication by 
the gyrase–quinolone complex on DNA. 
2. Mechanism B: does not require RNA and protein synthesis and can act on bacteria that are 
unable to multiply. Mechanism B (chloramphenicol insensitive) can be correlated with dislocation 
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3. Mechanism C: requires RNA and protein synthesis but does not require cell division. 
Mechanism C may correlate with trapping of topoisomerase IV complexes on DNA. 
Moreover, survival curves show that when the fluoroquinolone concentration is near the minimal 
inhibitory concentrations (MIC) of the bacterium, the drug has a static effect on bacterial growth 
(bacteriostatic). As the drug concentration increases relative to the MIC of the bacterium, bacterial 
killing increases up to a certain drug concentration (termed the optimum bactericidal 
concentration). As concentrations exceed the optimum bactericidal concentration, further 
increases in drug concentration can lead to a decrease in bacterial killing (Martinez et al., 2006). 
2.1.1.4 Pharmacokinetics of fluoroquinolones 
Fluoroquinolones show to be well absorbed and distributed in tissues and body fluids after oral 
subcutaneous and intramuscular administrations in different animal species. However, food intake 
and tissue binding can decrease its absorption. High and major concentrations of fluoroquinolone 
are found in the kidney and liver. This can be due to the fluoroquinolones high lipophilicity, 
passing well the cell membranes and are not easily expelled. In addition, fluoroquinolones show 
the ability to be concentrate more on leukocytes that allows them to be transported to the site of 
infection, acting more on infected tissues than healthy ones (Papich & Riviere, 2009). 
The main metabolites of fluoroquinolones are the 3-carboxylated derivatives that are produced by 
kidney and the hydroxylated derivatives. The letter compounds are more water-soluble, and 
therefore more easily eliminated than the parental drug. This type of metabolism produces both 
active and inactive products.  
The main route of elimination of the fluoroquinolones is kidney. This drug having a partially acidic 
feature, are eliminated for active tubular secretion, reaching higher urinary concentrations than 
serum. They are re-absorbed in a higher percentage in the animal species that have acid urine, 
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fluoroquinolones and their metabolites can also be eliminated by the bile duct (Odore & Badino, 
2009). 
2.1.1.5 Antimicrobial resistance  
Antimicrobial resistance is a complex problem that is likely to require attention at many levels. 
The most frequently developed resistance to fluoroquinolones is related to: 
 i) modification of the target structure, that is, the mutation of the gyrA gene, which encodes for 
the subunit A of DNA-gyrase, resulting in the transcription of a different subunit that is not 
recognized by fluoroquinolone; ii) mutation of the paro-gene (responsible for breaking DNA) of 
Topoisomerase IV. This type of alteration is common in Gram positive bacteria; iii) alteration of 
the outer membrane permeability, which involves the bacterial cell, a cross-resistance with other 
antibiotics that use porinic channels to enter the periplasmic space. This mechanism is typical of 
some Gram negative strains (Ferrero et al., 1995). 
Issues concerning the optimal dose to administered are addressed by the mutant selection window 
hypothesis. This hypothesis maintains that drug-resistant mutant subpopulations present prior to 
initiation of antimicrobial treatment are enriched and amplified during therapy when antimicrobial 
concentrations fall within a specific range (the mutant selection window). The upper boundary of 
the mutant selection window is the MIC of the least drug susceptible mutant subpopulation, a value 
called the mutant prevention concentration (MPC). The lower boundary of the mutant selection 
window is the lowest concentration that exerts selective pressure, often approximated by the 
minimal concentration that inhibits colony formation by 99% (MIC99) (Drlica & Zhao, 2007). 
Figure 8 shows the mutant selection window (MSW) characterized by three discrete 
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B: Concentration above the MIC of the wild-type bacteria, where there is a plateau in killing due 
to the survival of the least susceptible microbial subpopulation of the first-step resistant variant. 
C. Concentrations at which even the least susceptible organism are killed (MPC). Above MPC all 
bacteria are inhibited or eliminated. The concentration of the administered drug should therefore 
remain as low as possible in this range (MSW) and pass over the MPC threshold to obtain good 
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2.1.1.6 Levofloxacin 
 
Figure 9. Levofloxacin 
 
Levofloxacin belongs to third generation fluoroquinolones (Figure 9). It is an optical isomer of 
ofloxacin having two-fold higher antimicrobial activity than the parent compound. Compared with 
other fluoroquinolones it has more pronounced bactericidal activity against Pseudomonas, 
Enterobacteriaceae and Klebsiella,spp, several species of staphylococci, streptococci including S. 
pneumoniae, bacteroides, clostridium, haemophilus, moraxella, legionella, mycoplasma and 
chlamydia (North et al., 1998). The bactericidal effect of levofloxacin is obtained through a 
reversible linkage with DNA excretion and subsequent inhibition of bacterial DNA replication 
(Figure 10) (Fu et al., 1992).  
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Levofloxacin distributes well in all body tissues and fluids of the respiratory tract, skin, urine and 
prostrate, and its uptake by cells makes it suitable for use against intracellular pathogens. However, 
it penetrates poorly into the central nervous system. Like all fluoroquinolones, levofloxacin shows 
a concentration-dependent killing mechanism, whereby the optimal effect is attained by the 
administration of high doses over a short period of time. This concentration-dependent killing 
profile is associated with a relatively prolonged postantibiotic effect. The drug undergoes a limited 
metabolism in rats and humans and is primarily excreted by kidney mainly as active drug. Inactive 
metabolites (N-oxide and demethyl metabolites) represent <5% of the total dose (Goudah & Abo-
El-Sooud, 2008) The pharmacokinetics of levofloxacin has been fully investigated in humans 
(Chulavatnatol et al., 1999), rabbits (Destache et al., 2001), cats (Albarellos et al., 2005) and calves 
(Dumka & Srivastava, 2006, 2007). Currently, Levofloxacin is successfully used in human 
medicine for the treatment of infections of upper and lower respiratory tract, genitourinary system, 
skin and soft tissue (Patel et al., 2009).  
2.1.2 Macrolides 
The macrolide class of antibiotics contain a 14-, 15-, or 16-membered macrocyclic lactone ring to 
which amino sugars are attached (Odore & Badino, 2009). The unique structure of macrolides 
facilitates rapid dissemination from the central compartment to lung tissues which make them 
useful in the treatment of bacterial pneumonia (Clothier, 2010). Macrolides are classified in natural 
macrolides, originally isolated from Streptomyces such as erythromycin and semi-synthetic 
macrolides like clarithromycin and azithromycin. 
Macrolides present a bacteriostatic action for the binding to the 50S ribosomal subunit, preventing 
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Figure 11. Mechanism of action of macrolides 
 
Due to its mechanism of action the spectrum of action includes Gram positive bacteria, 
mycoplasma, rickettsia, chlamydia, some protozoa such as amoeba, toxoplasmosis and 
cryptosporidium. Due to its basic nature and liposolubility, macrolides are generally well absorbed 
orally. The percentage of plasma protein binding is not high (about 20-40%) in different animal 
species. Macrolides distribute well in all organs and tissues except the SNC, spreading 
intracellularly to reach concentrations higher than plasma concentrations. The basic nature of this 
class of drugs led to higher concentrations in saliva and liquids with acidic pH such as milk where 
they reach levels up to 3 times higher compared to plasma concentrations. In the peripheral 
compartment, macrolides concentrations are elevated, particularly in the lung, liver, kidney and 
spleen. Macrolides are bio-transformed in different percentages through N-demethylation 
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(about 80%) in conjugated compound forms and may undergo the entero-hepatic uptake (Odore 
& Badino, 2009). This class of drugs is used in farm animals for respiratory disease, streptococcal 
and staphylococcal mastitis in ruminants, arthritis in bovine, enteritis haemorrhagic in the pig and 
oral cavity infections (Odore & Badino, 2009). 
2.1.2.1 Tulathromycin 
 
Figure 12: Tulathromycin 
 
Tulathromycin (Figure 12) is an antimicrobial drug belongs to the class of semi-synthetic 
macrolide consisting of a regioisomeric, equilibrated mixture of a 13-membered ring azalide 
(10%) and a 15-membered ring azalide (90%) but in aqueous media the drug exists as an 
equilibrated mixture. The drug molecule has three nitrogen/amine functional groups representing 
the first member of a novel sub–class of macrolides known as triamilides. Tulathromycin is a basic 
molecule with a pKa in a range from 8.6 to 9.6 and it is approximately 50 times more soluble in 
hydrophilic than hydrophobic media. This physicochemical feature allows the unionized fraction 
of the drug to easily penetrate into tissues from plasma and to accumulate in compartments with 
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large volume of distribution of the drug and the accumulation of the drug in alveolar epithelial 
lining fluid and bronchoalveolar lavage cells. This activity can provide unique therapeutic 
advantage in treating bacterial respiratory infections in livestock species (Villarino et al., 2013a). 
Finally, tulathromycin has been shown to accumulate in leukocytes (primarily macrophages and 
neutrophils) in greater amounts than older macrolides (Evans, 2005). 
As a macrolide, tulathromycin exerts its mechanism of action through binding to the 50S subunit 
of bacterial ribosomes and blocking peptidyl transferase which results in dissociation of transfer 
RNA (tRNA), cessation of peptide translocation, and blockage of protein synthesis (Benchaoui et 
al., 2004; Evans, 2005). Although this drug, like other macrolides, is classified as bacteriostatic 
agent when tested against Staphylococcus aureus and E. coli (Pfizer, 2004), it can also exhibit 
bactericidal activity at higher concentrations (Benchaoui et al., 2004; Evans, 2005; Nowakowski 
et al., 2004). This effect is dictated by the microorganism involved in the infection and the 
concentration-time profile of the drug at the site of infection. In particular, tulathromycin present 
a bactericidal effect at 4x and 8x the MIC against M. haemolytica, A. pleuropneumoniae and P. 
multocida (Villarino et al., 2013b). 
The pharmacokinetics of tulathromycin, have been studied in different animal species such us 
mice, cattle, pigs, goats and foals. At label dose (2.5 mg/kg) in cattle and swine species, 
tulathromycin is characterized by a rapid rate of absorption and large systemic availability (90%) 
after IM and SC administration. In plasma, tulathromycin has a long terminal half-life, ranging 
across domestic species from 60 to 140 h and a remarkable large volume of distribution (>10 L/kg). 
In pigs, most of the dose is eliminated as unchanged by biliary and renal excretion. Protein binding 
studies indicate that the unbound fraction of tulathromycin ranges from 53% to 68%. Lung 
pharmacokinetic studies in cattle, pigs and horses reveal an extraordinary capacity of 
tulathromycin to accumulate in lung tissue, where the lung homogenate concentrations showed to 
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tulathromycin has been addressed in several published studies including data on cattle, swine, 
horses, and goats.  
Tulathromycin is safe when used according to label directions (Pfizer, 2005) but studies of toxicity 
in bovine, swine and caprine species have revealed minor clinical and injection site 
histopathological changes that have been  resolved over time (Pfizer, 2005; Clothier et al., 2010). 
Moreover, hypersalivation, head shaking, and pawing at the ground have been reported at 
therapeutic doses (Pfizer, 2005). 
 
2.2 Pain relief drugs 
Pain is a sensory process that results from tissue damage and is intended to prevent further tissue 
damage that follows the injury. Pain activates numerous physiological reactions that often induce 
negative effects on well-being and behaviour, as well as on the growth and reproduction of the 
animals. However, the main obstacle to the pain management, in farm animals, is to recognise, 
quantify and evaluate the pain status of each individual and treat without disturbing the whole 
group of animals (Guatteo et al., 2012). In veterinary medicine, recently, pain has been shown to 
affect animal welfare and production, and the interest in the field of analgesia has been drastically 
increasing (Lee et al., 2014). Therefore, the desirable medication associated with the pain status 
of each individual will be important to treat pain in farm animals. A similar specific approach 
designed to minimize pain in laboratory animals is also required in farm animals. Nowadays, the 
concepts of “Replacement, Reduction and Refinement”, called the ‘3Rs’ (Russell & Burch, 1959), 
used in the design of animals experiments to minimise unnecessary pain, is the basis of a new 
approach the ‘3S’ “Suppress, Substitute and Soothe pain”. This approach is used to review existing 
practical solutions and find new solutions to eliminate or alleviate pain in farm animals. It is based 
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“substitute” such procedures by others causing less pain and to “soothe” pain when it cannot be 
avoided (Guatteo et al., 2012). 
Animal welfare issues in food production are now being driven by animal activists, food 
companies and consumers. Consequently, animal welfare assurance programs have been 
developed and are encoded in non-mandatory codes or guidelines, government regulations, inter-
governmental agreements and corporate programs (Fraser, 2006). One of the measures aimed at 
improving animals welfare is pain management by using anti-inflammatory drugs. These 
substances can be effective in suppressing or preventing inflammation, treating allergy, lowering 
fever and reducing pain. The classes of anti-inflammatory drugs differ because of their actions 
towards the biochemical mediators that are released during inflammation and that propagate the 
inflammatory response (De Vito, 2015).  
2.2.1 Opioid receptor agonists 
One of the main classes of anti-inflammatory drugs most used in veterinary medicine for food-
producing animals are opioid receptor agonists. Unfortunately, the drugs in these classes range 
present typical side effects. Compounds that activate opioid receptors, in particular the Mu Opioid 
Receptor (MOR) subtype has been used for decades in the treatment from moderate to severe pain 
(Meldrum, 2003). Extensive clinical experience with the prototypical MOR agonist morphine 
indicates that, although this compound is very effective against acute pain, it may be less effective 
for conditions precipitating chronic pain, especially neuropathic pain or pain of inflammatory 
origin. This reduced effectiveness for chronic pain is due to the MOR down regulation with long-
term therapies; a substantial increase in dosing is required in order to maintain a clinically 
satisfactory analgesic effect (Dickenson & Suzuki, 2005). Furthermore, morphine has a limited 
therapeutic window, its analgesic effect generally coincides with several side effects (nausea, 




Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
chronic pain. Another therapeutic approach has been to combine the MOR activation with an 
additional compound that provides analgesia via a different mechanism of action, resulting in an 
opiate-sparing effect. Activation of the noradrenergic descending pain inhibitory pathway could 
be considered a candidate for such an additional mechanism (Wang et al., 2008). Active 
ingredients that inhibit the reuptake of noradrenalin (NA) are effective analgesics, particularly in 
chronic pain conditions. The first molecule showing this dual mechanism of action was tramadol. 
It produces MOR activation as well as inhibition of serotonin (5HT) and NA reuptake. Nowadays, 
tramadol is widely used in veterinary clinical practice but its efficacy is still controversial for its 
faster metabolism to inactive metabolites N-desmethyl tramadol (M2) and O,N-didesmethyl 
tramadol (M5), from different animal species such as goats, dogs, horses, lamas, alpacas, peafowl, 
hawks than in cats (Giorgi, 2012). 
2.2.1.1 Tapentadol 
 
Figure 13. Tapentadol 
 
Tapentadol is a novel opioid drug launched at the end of 2011on the European market for human 
use (Figure 13). This drug, like tramadol, presents a dual mechanism of action: the mu-opioid 
receptor agonism and the inhibition of noradrenaline-reuptake. Based on its unique mechanism of 
action, it has been proposed as the first representative of a new pharmacological class of centrally 
acting analgesics: the MOR agonist, NA Reuptake Inhibitor (MOR-NRI) (Kress, 2010). 
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a 2-3-fold difference after systemic administration. This finding, consistent across different pain 
relief evaluation models, may be due to a better brain penetration of tapentadol, but also suggests 
that the NA reuptake-inhibitory property, contributes to a more potent analgesia that would be 
expected solely from its MOR agonism (Tzschentke et al., 2006). Given the moderate affinity of 
tapentadol at the MOR and the opioid sparing effect of tapentadol NRI component, it seems logical 
that this drug would produce fewer opioid-related side effects than classical MOR agonists, such 
as morphine. Indeed, compared to morphine, tapentadol produces much less nausea and vomiting 
in ferrets, the duration of these side effects was also shorter (Tzschentke et al., 2009). Furthermore, 
the threshold dose for these effects was 100 times higher for tapentadol than for morphine. In vivo 
and in vitro preclinical pharmacological studies demonstrated that tapentadol displays weak 
anticholinercic activity and a negligible 5HT reuptake inhibition but a pronounced NA reuptake 
inhibition (Tzschentke et al., 2006). Following its chronic administration, tolerance development 
took much longer compared with morphine (Ahlbeck, 2011). The PK features of tapentadol have 
been tested in rodents and humans. In summary, the drug is almost completely absorbed after oral 
administration but undergoes high levels of phase II metabolism glucuronidation, limiting oral 
bioavailability at 8 and 32% in rats and humans, respectively. Phase I biotransformation is 
negligible and does not produce active metabolites. Finally, tapentadol has shown no potential for 
CYP450 induction or inhibition (Terlinden et al., 2007). However, tapentadol still has some 
disadvantages. It has weak anti-muscarinic activity, which produces a well known adverse effects. 
Tapentadol is a weak blocker of 5-HT3 receptor (e.g., as mirtazapine, metoclopramide and 
ondasteron), as yet it has not been determined whether this property is helpful or harmful. It has 
very low oral bioavailability although animal species deficient of glucuronic acid, might be much 
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2.2.2 Non steroidal anti Inflammatory drugs  
Another major classes of anti-inflammatory drugs most used in veterinary medicine for food-
producing animals are the non-steroidal anti-inflammatory drugs (NSAIDs). The NSAIDs are 
widely used because of their ability to reduce inflammatory process. NSAIDs can be classified 
into several groups according to their chemical structure. The propionic acid derivatives 
(Ketoprofen, Carprofen, Vedaprofen , Naproxen); the anthranilic acid derivatives (Tolfenamic 
acid, Mefenamic acid); the nicotinic acid derivatives (Flunixin); the pyrazolones 
(Phenylbutazone]) and the acetic acid derivatives (Diclofenac); the class of oxicams 
(Meloxicam) (Dubreil-Chéneau et al., 2011). In veterinary practice, NSAIDs are used in the 
treatment of musculoskeletal disorders, coliform mastitis, pulmonary diseases and enteritis in 
several animal species. NSAIDs, however, because of their toxicity, can affect the gastro-
intestinal, hematopoietic and renal systems. Gastro-intestinal ulcerations are the most common 
and serious side effect of NSAIDs, especially in cases of overdose or chronic abuse (Kim et al., 
2014; 2015).  
2.2.2.1 NSAID mechanism of action 
The major mechanism of action by which the NSAIDs elicit their therapeutic effects (antipyretic, 
analgesic, and anti-inflammatory activities) is inhibition of prostaglandin (PG) synthesis. 
Specifically NSAIDs competitively (for the most part) inhibit cyclooxygenases (COXs), the 
enzymes that catalyze the synthesis of cyclic endoperoxides from arachidonic acid to form. Two 
COX isoenzymes have been identified: COX-1 and COX-2. COX-1, expressed constitutively, is 
synthesized continuously and is present in all tissues and cell types, most notably in platelets, 
endothelial cells, the GI tract, renal microvasculature, glomerulus, and collecting ducts. Thus 
COX-1 is important for the production of prostaglandins of homeostatic maintenance, such as 
platelet aggregation, the regulation of blood flow in the kidney and stomach, and the regulation of 
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gastrointestinal toxicity. COX-2 is considered an inducible isoenzyme, although there is some 
constitutive expression in the kidney, brain, bone, female reproductive system, neoplasias, and 
gastrointestinal tract. The COX-2 isoenzyme plays an important role in pain and inflammatory 
processes. Generally, the NSAIDs inhibit both COX-1 and COX-2. Some of the NSAIDs are 
mainly COX-1 selective (eg, aspirin, ketoprofen, indomethacin, piroxicam, sulindac). Others are 
considered slightly selective for COX-1 (eg, ibuprofen, naproxen, diclofenac) and others may be 
considered preferentially selective for COX-2 (eg, etodolac, nabumetone, and meloxicam) 
(DeRuiter, 2002). A benefit of this latter class is that it seems to lower the adverse effects triggered 
by the classical NSAID drugs. On the other side, the COX-2 inhibitor drug pharmacokinetic and 
pharmacodynamic profiles can change from species to species. 
2.2.2.2 Meloxicam 
 
Figure 14. Meloxicam 
 
Meloxicam (Figure 14) is a potent anti-inflammatory drug belonging to enolic acid group of the 
oxicam class, having analgesic and antipyretic properties. The acidity of the oxicams (pKa=6.3). 
is attributed to the 4-OH with the enolate anion being stabilized by intramolecular H-bonding to 
the amide N-H group. Also, the presence of the carboxamide substituent at the 3-position of the 
benzothiazine ring contributes toward acidity by stabilizing the negative charge formed during 
ionization (resonance stabilization) (DeRuiter, 2002). Meloxicam, if compared to the common 
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(12 times more selective COX-2 inhibitor in the dog) than COX-1 isoenzyme, preventing the 
occurrence of inflammation by the inhibition of prostaglandin production that sensitize the afferent 
nociceptors at peripheral sites of inflammation (Kay et al., 2000). This mechanism of action results 
in a lower ulcerogenic side effect and gastrointestinal irritation (Wani et al., 2013; Wani et al., 
2014). 
The pharmacokinetic profile of meloxicam, if compared to the common NSAIDs, showed a good 
absorption, longer elimination half-life and high extravascular bioavailability in different animal 
species: dogs (Hare et al., 2012; Montoya et al., 2004; Busch et al., 1998), cats (Lehr et al., 2010; 
Giraudel et al., 2005), horses (Lees et al., 1991; Toutain and Cester, 2004; Toutain et al., 2004; 
Burns et al., 2010), rabbits (Turner et al., 2006; Carpenter et al., 2009), turtles (Di Salvo et al., 
2015), green iguana (Divers et al., 2010), piglets (Alassane et al., 2010; Fosse and Spadavecchia, 
2011), cattle (Johnn et al., 2011; Coetzee et al., 2007; Coetzee et al., 2012), camels (Wasfi et al., 
2012), Ilama (Amanda et al., 2012) and small ruminants (Shukla et al., 2007; Ingvast-Larssom et 
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3. Ex vivo antibacterial activity of levofloxacin against E. coli and its 
pharmacokinetic profile following intravenous and oral administrations in 
broilers 
  
Nowadays, farms are organized in cluster breed system, an intensive breeding technique that 
requires specific prevention and treatment strategies to prevent and manage infectious diseases 
(chapert 2) (Landoni & Albarellos, 2015). Few drugs are approved and labelled for poultry species 
and, if the animals are mistakenly or intentionally treated with a drug that is prohibited from extra-
label drug use, the exposed animals should not enter the food chain unless permission is granted 
from the proper authorities. The inappropriate dosage regimens or extra-label use of drug leads to 
edible tissues containing veterinary drug residues that can pose risks to human health, including 
direct toxic effects and allergic reactions (Goetting et al., 2011). Moreover, off-label drugs can 
contribute to the development of bacterial resistance in animals and humans. Thus, it has been 
suggested that the optimal dosing regimen should be determined to maximize the therapeutic 
efficacy and to minimize the risk of resistance emerging during treatments (Ambrose et al., 2007; 
Toutain & Lees, 2004).  
In poultry, antibiotics are used extensively for disease prevention and treatment. In the United 
States, antibiotics are also used for growth promotion, although this type of use has been prohibited 
in the EU since 2006 (Goetting et al., 2011). Levofloxacin (LEVO) is a third generation 
fluoroquinolone labelled for use in humans, and it has excellent anti-bacterial activity. Although 
this antibacterial is not registered in veterinary medicine, several PK studies recently demonstrated 
that it could be successfully used in calves, goats and poultry (Dumka, 2007; Goudah & Abo El 
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3.1 Aim of the study 
The aim of the study was to:  
i) Evaluate pharmacokinetics and tissues disposition of LEVO after intravenous (IV) and oral (PO) 
administrations at the dose of 5 mg/kg in broilers.  
ii) To calculate the MIC and MBC in two matrices (serum and broth) of LEVO against E. coli, 
iii) To assess in vivo and ex vivo antibacterial effects of LEVO against E. coli using time kill 
experiment,  
iiii) To predict the optimal doses corresponding to bacteriostatic, bactericidal and eradication 
effects basing on AUC24h/MIC parameter for PK/PD modelling.  
 
3.2 Material and methods 
3.2.1 Chemicals, reagents and solutions 
Pure LEVO and enrofloxacin considered as internal standard (IS) (standards purity >99.0%), were 
purchased from Sigma-Aldrich. 
Singular stock solutions of LEVO and IS in MeOH were diluted to prepare a 6-point calibration 
curve at the following concentrations 5, 1, 0.500, 0.250, 0.100, 0.050 μg/mL and 2, 1, 0.500, 0.250, 
0.100, 0.050 μg/mL, of LEVO in plasma and organs respectively. The analyte was stable for at 
least 10 weeks if stored at 4°C 
3.2.2 Animal experiments 
The animal experiment was performed at the University of Agriculture, Faculty of Veterinary 
Medicine, Jelgava, Latvia. Sixty-five healthy broiler chickens, 35 days old, with an average weight 
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examination through observation of behavior, appetite and the absence of drug treatment and 
parasites assessed that animals were in good health status. Animals were acclimated for a 2-weeks 
prior to beginning of the study. During this period, chickens were housed in an indoor area all 
together on the floor. Animal care and handling were performed according to the EC council 
Directive 2010/63 and also according to Institutional Animal Care and Use directives issued by 
the Animal Welfare Committee of Latvia (authorization n° 025564), which approved the study 
design. The day before the commencement of the experiment, animals were randomly divided (65 
slips of paper marked with the numbers 1 to 65 selected blinded from a box) into 4 groups: groups 
A, B and C with 20 subjects and group D with 5 subjects. A ring with an identification code was 
applied to the right leg of each animal. Animals were then moved to cages (4 chickens/cage) until 
the end of the experiment. Water was provided ad libitum. Standard management practices were 
followed to keep animals free from stress. Groups A, B and C received LEVO at the dose rate of 
5 mg/kg of body weight (Levofoxacin Kabi 5 mg/mL, Kabi) according to a randomized, parallel 
study design. Group. After overnight fasting, A and B groups received LEVO orally directly into 
the chickens' crop using a 18-gauge metal ball-tipped gavage connected to a 2.5 mL syringe. Group 
C received the drug intravenously through the vein of the right wing using a 2.5 mL syringe and 
26- gauge needle. Group D received saline solution by oral administration thought the same 
method reported for the administration of drug by oral route (groups A and B). Concerning blood 
collections, samples (0.7 mL) were collected in group A and C at time 0 (prior drug administration) 
5, 30 min, and 1, 4, 6, 8, 10, 24, 48 h using IV catheter (Venflon 24Gx25mm) fixed into the left 
wing vein. After centrifugation at 400xg for 10 min plasma and serum were separated and split 
into two aliquots, for PK and PD analysis, respectively, and stored at -20 °C until use within 30 
days from collection. Animals in group B were divided in 5 sub-groups (n = 4) and euthanized 
through cervical dislocation at 1, 6, 10, 24 and 48 h after the administration of the drug for organs 




Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
washed in saline and stored at -80 °C until analysis. In order to get control blood and organs for 
analytical purposes, animals in group D (control group) were bleed and organs collected at 1, 6, 
10, 24 and 48 h (one animal for each point) (Figure 15). 
 
 
Figure 15. Animal experiments 
 
3.2.3 Analytical method 
3.2.3.1 Instrumentation and chromatographic conditions 
The analytical method was performed at the University of Pisa, Department of Veterinary 
Sciences, Italy. The HPLC system was an LC system (Jasco Inc.) consisting of a high-pressure 
mixer pump (model PU 980 Plus), spectrofluorometric detector (model 2020 Plus), and a loop of 
50 μL. Data were processed using Borwin software. Chromatographic separation assay, based on 
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using a Gemini C18 analytical column (250 x 4.6-mm inner diameter, 5-μm particle size, 
Phenomenex) maintained at 25 ° C. The mobile phase consisted of acetonitrile:aqueous solution 
(20:80 v/v%) at a flow rate of 1mL/min. The aqueous solution consisted of potassium dihydrogen 
phosphate (0.02 M), and 860 µL of tetraethylamine (0.012 M) in water adjusted to pH 4 with 
orthophosphoric acid (0.006 M). Excitation and emission wavelengths were set at 295 and 490 
nm, respectively. 
3.2.3.2 Sample preparation 
The procedure of LEVO extraction from plasma and organs was based on that previously reported 
by Giorgi et al., (2013) with slight modifications. Concerning plasma samples, aliquots (0.2 mL) 
of plasma were added to 0.1 mL of IS (10 µg/mL) diluted with 800 mL of 0.1M phosphate buffer 
at pH 7.1. After adding 4 mL of a mixture of trichloromethane : isopropanol (5:1 v/v), the samples 
were shaken at 200 oscillations/min for 10 min and centrifuged at 4000 x g for 5 min. Three mL 
of the organic layer was transferred into a clean tube and dried at 40 ° C under nitrogen stream. 
The residue was dissolved in 0.2 mL MeOH, vortexed, and an aliquot was injected onto the 
chromatographic system. About the organ extractions, liver, kidney, lung and muscle were 
defrozen and immediately dissected into small pieces. A total of 1 g per each sample was placed 
into 10 mL glasses tubes and was added to 3 mL of homogenization reagent consisting of 0.1M 
phosphate buffer at pH 7.1. The suspension was homogenized using an Ultra Turrax for 1 min. 
Internal standard aliquots of 0.1 mL of IS (10 µg/mL) was added to 500 µL of suspension and 
vortexed for 1 min. Four mL of a mixture of trichloromethane:isopropanol (5:1 v/v) was added 
and the samples were shaken at 200 oscillations/min for 10 min and centrifuged at 4000 x g for 5 
min. Three mL of the organic layer was transferred into a clean tube and dried at 40°C under 
nitrogen stream. The residue was dissolved in 0.2 mL MeOH, vortexed, and an aliquot was injected 
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3.2.3.3 Sample quantification 
Standard curves were constructed with standard LEVO concentrations vs. ratio of LEVO /internal 
standard peak areas. Linearity of the regression curves in the range 50-5000 ng/mL and 50-2000 
ng/mL for plasma and organs respectively were assessed on the basis of the residual plot, the fit 
test and the back calculation (within 20% of known amount). Limit of detection (LOD) and limit 
of quantitation (LOQ) were determined as analyte concentrations giving signal-to-noise ratios of 
3 and 10, respectively. The quantitative HPLC method for plasma and each organs were validated 
by examining the measurement of consistency of results (within-run and between-run), correlation 
(coefficient of determination of the standard curve), and extraction efficiency of the assay. The 
within-run precision was calculated from similar responses from six repeats of three control 
samples (10, 500, and 1000 ng/mL) in one run. The between-run precision was determined by 
comparing the calculated response (in ng/mL back-fit of the standard curve) of the low (10 ng/mL), 
middle (500 ng/mL), and high (1000 ng/mL) control samples over three consecutive daily runs 
(total of six runs). The assay accuracy for within-run and between-run was established by 
determining the ratio of calculated response to expected response for low (10 ng/mL), middle (500 
ng/mL), and high (1000 ng/mL) control samples over six runs. The extraction efficiency was 
determined by comparing the response (in area) of low, middle, and high standards, and the 
internal standard, spiked into blank plasma eluent before evaporation, to the response from 
equivalent extracted standards. 
3.2.4 Pharmacokinetic analysis 
Pharmacokinetic parameters for IV and PO administration were determined individually as a non-
compartmental model using WinNonlin 5.3.1 software (Pharsight).  
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3.2.5 Serum protein binding 
The ultrafiltration method was used according to Whitlam & Kenneth (1981). Five ranges of 
LEVO concentrations (10, 50, 100, 500, 1000 ng/mL) were used to determine the % of binding. 
Each experiment was run in triplicate. The EMIT free level filter system (Syva Co., Palo Alto, 
CA) was used for the ultrafiltration. One mL of serum spiked with various concentrations of LEVO 
was placed in the filter. The samples were centrifuged for 10 min at 2000 x g, 37° C. The obtained 
ultra-filtrate containing free LEVO underwent HPLC analysis.  
3.2.6 Pharmacodynamic analysis 
The PD analysis was performed at the, University of Turin, Department of Veterinary Sciences, 
Turin, Italy. 
3.2.6.1 Isolation of Escherichia coli 
Two field Escherichia coli isolates were collected from cloacal swabs of healthy broiler chickens. 
Animals were housed in a poultry farm near Turin (Italy) and no pharmacological treatments have 
been administered in the previous two months. The samples were cultured on MacConkey agar 
(Oxoid) and incubated at 37 °C overnight. Lactose-fermenting, indole-positive colonies were 
evaluated using the BBL Crystal test (Becton Dickinson). Then, the identified E. coli colonies 
were stored in Luria-Bertani broth (Oxoid) containing 15% glycerol at -80 °C until further testing. 
American Type Culture Collection (ATCC) strain of E. coli 25922 was also used in this study as 
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3.2.6.2 Determination of MIC and MBC values in broth and in serum 
Minimal inhibitory concentration (MIC) was determined in broth and in serum obtained from 
healthy broiler chickens using the microdilution method according to Clinical and Laboratory 
Standards Institute (CLSI) guidelines (CLSI, 2009). Briefly, E. coli strains were seeded on 
Trypticase Soy Agar (TSA) (Oxoid). Colonies from overnight growth were directly suspended in 
Mueller-Hinton broth (MHB) (Oxoid) to obtain a turbidity comparable to the McFarland turbidity 
standard of 0.5. Cultures were diluted 1:100 with broth to reach a final concentration of 106 colony 
forming units (CFU)/mL. LEVO solution (final concentration of 64 μg/mL) was added either to 
MHB or to serum obtained from the control broiler chickens. Serial dilutions from this solution 
were prepared in broth and in serum to reach concentrations ranging from 32 μg/mL and 0.008 
μg/mL, and in presence of approximately 5×105 CFU/mL. Plates were incubated at 37 °C for 18 h 
and read at 600 nm, using the Ultraspec 2000 Spectrophotometer (Pharmacia Biotech, New Jersey, 
USA). The MIC was reported as the lowest concentration of tested drug able to inhibit bacterial 
growth. From the wells showing no visible sign of growth/turbidity in MIC determination, bacteria 
were transferred into TSA plates by streak plate method. The plates were then incubated at 37 °C 
for 24 h. The smallest concentration showing no growth of tested organisms was considered as the 
minimum bactericidal concentration (MBC). MIC and MBC of LEVO against E. coli ATCC 
25922 were determined only in MHB, whereas the same parameters were evaluated for the 
sensitive field strains both in MHB and in serum. All experiments were performed in triplicate. 
3.2.6.3 In vitro bacterial killing curves 
Twenty blood samples were obtained from no treated healthy broiler chickens. The animal samples 
were collected in a poultry farm near Turin (Italy). Samples were collected prior the slaughtering. 
Blood samples were placed at room temperature for 60 min and then centrifuged at 2000 g for 
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culture of the sensitive field E. coli strains were suspended in 9 mL MHB and incubated for 20 h 
at 37 °C. Solutions of LEVO in serum (1 mL) were prepared at the following concentrations: 0.0 
μg/mL (control), 0.03 μg/mL, 0.06 μg/mL, 0.125 μg/mL, 0.25 μg/mL, 0.5 μg/mL, and 1 μg/mL. 
These solutions were added in presence of 10 μL broth culture in order to reach the final 
concentration of 2×107 CFU/mL, approximately. To determinate colony forming units, serial 
dilutions from 10–2 tо 10–6 in sterile saline were prepared (control = 10–8) and were incubated for 
3, 6 and 24 h at 37 °C. Then, 10 μL of each dilution were inoculated on TSA and colony-forming 
units were counted after 16 h. The countable dilution is the dilution that gives 3 to 30 colonies per 
10 µL drop of sample dispensed (Herigstad et al., 2001). All experiments were performed in 
triplicate. 
3.2.6.4 Ex vivo bacterial killing curves 
Eight to ten colonies from overnight growth of E. coli in TSA (as mentioned above) were used to 
inoculate 9 mL of MHB, and then incubated overnight at 37 °C. To each 0. 5 mL serum sample 
from treated animals, 5 µL of the stationary-phase bacterial cultures was added to give a final 
concentration of approximately 3×107 CFU/mL. To determine the numbers of CFU, serial 
dilutions (ranging from 10-2 to 10–6) were prepared with sterile saline and incubated at 37 °C for 
3, 6, and 24 h. Thereafter, aliquots of 10 µL were plotted on TSA plates and the numbers of CFU 
were counted after 16-h incubations. The countable dilution is the dilution that gives 3 to 30 
colonies per 10 µL drop of sample dispensed (Herigstad et al., 2001). All experiments were 
performed in triplicate. 
3.2.7 PK/PD integration and optimal dose determination 
For PK/PD integration, the indices, in vivo Cmax/MIC and AUC24h/MIC, were calculated by linking 
PK data with PD index (MIC) for serum after oral administration of LEVO in clinically isolated 
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vivo time killing curve and fitted using the sigmoidal inhibitory Emax model following equation 
(Eq. 7): 
 







where Emax is the log10 difference in bacterial counts in the test sample containing LEVO after 24 
h of incubation when the limit of detection is reached; E0 is the log10 difference in bacterial counts 
in control sample (without drug) after 24 h incubation compared to the initial inocula log10 count 
in samples incubated between time 0 and 24 h; Ce is the ex vivo AUC24h/MIC in the effect 
compartment; and N is the Hill coefficient which describes the steepness of the ex vivo 
AUC24h/MIC-effect curve. These PD indices were calculated using a non-linear regression 
software (WinNonlin, USA). The antibacterial effect of LEVO was quantified from the sigmoidal 
inhibitory Emax model for three levels of growth inhibition: bacteriostatic (no change in bacterial 
count from control zero time count), bactericidal effect (99.9% reduction in bacterial count) and 
bacterial eradication (the lowest ex vivo AUC24h/MIC that produced a reduction in bacterial counts 
to the limit of detection). Thus, the values of ex vivo AUC24h/MIC for bacteriostatic and 
bactericidal effect were the values which produce E = 0 and -3, respectively. 
Using PK/PD modelling, the optimal oral dose in broilers were predicted and calculated using the 
following equation (Eq. 8) (McKellar et al., 2004): 
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where, Cl is the clearance; ex vivo AUC24h/MIC is the ex vivo AUC24h/MIC ratio for optimal 
efficacy; F is the bioavailability; MIC is the minimum inhibitory concentration; fu is the free 
fraction of drug in plasma. 
3.2.8 Statistical analysis 
PK and PD data were expressed as mean ± SD, except for PK/PD indices which were presented 
as mean ± SE. Statistical comparison of PK parameters was determined with Student’s t-test and 
performed by Excel program (Microsoft). 
 
3.3. Results 
3.3.1 Pharmacokinetic analysis  
No adverse effects were observed during the experiment. Following IV and PO administration of 
LEVO at 5 mg/kg, the plasma concentration vs. time curve is illustrated in Figure 16.  
 
Figure 16. Mean plasma concentration vs. time curve of levofloxacin after IV (—○—) 
and PO (--□--) administrations at 5 mg/kg in broilers. Bars represent the SD. 
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LEVO concentration for IV and PO were detectable in the plasma up to 24. Pharmacokinetic 
parameters of LEVO were presented in Table 3.  
After a PO administration, LEVO showed fast absorption with the mean Tmax value of 0.88 h. The 
mean values of HLλZ for IV and PO were 6.93 and 8.09 h, respectively, but not statistically 
different between the two different routes of administration. The MRT was consistent between 
two groups. The AUMC0-last in PO group was significantly higher than that in IV group. The 
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Table 3. Pharmacokinetic parameters of levofloxacin after IV and PO administration 
at 5 mg/kg in broilers. 








0.99 ± 0.02 0.97 ± 0.04 
λZ 1/h 0.12 ± 0.04 0.09 ± 0.02 
HLλZ h 6.93 ± 2.94 8.09 ± 1.71 
Tmax h 
 
± / 0.88 ± 0.23 
Cmax ng/mL 
 
± / 1949 ± 382 
C0 ng/mL 3543 ± 2278 / ± / 
AUC0-24 h*ng/mL 12734 ± 3772 15695 ± 1464 
Vss mL/kg 2881 ± 1071 / 
 
/ 
V/F mL/kg 3599 ± 1335 3288 ± 659 
CL/F mL/hr/kg 381.17 ± 90.10 282.69 ± 26.42 
AUMC h*h*ng/mL 68569a ± 27012 108156 ± 9980 
MRT h 5.37 ± 1.31 6.90 ± 0.37 
F % / ± / 123.25 ± NA 
λZ, first-order rate constant; HLλZ, half-life of the terminal portion of the curve; Tmax, time at the maximum 
drug concentration; Cmax, maximum plasma drug concentration; C0, concentration at time 0; AUC0-24, area 
under the curve from 0 to the last; Vss, volume of distribution at steady state; V/F, volume of distribution 
during the elimination phase; CL/F, body clearance during the elimination phase; AUMC, area under the 
first moment curve from 0 to the last; MRT, mean residence time; F, absolute bioavailability. 
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3.3.2 Disposition of levofloxacin in tissues 
LEVO were found in the investigated tissues up to 48 h following oral administration at 5 mg/kg 
(Figure 17). At 1 h after oral administration, drug tissue concentrations in most organs were high 
and then decreased over time except in muscle. Maximum concentration in muscle was reached at 
6 h after administration. The highest levels of LEVO (6576 ± 1741 ng/mL) were observed in the 
liver. The concentrations of LEVO in kidney, lung and muscle were the next highest. The levels 
of LEVO were similar in liver and kidney, also, higher than those in muscle and lung. 
 
 
Figure 17. Tissue disposition of levofloxacin after PO administration at 5 mg/kg in broilers. Bars 
represent the SD 
 
3.3.3 Serum protein bound 
LEVO is approximately 20 to 30% bound to serum proteins. The average value was 24 ± 5 %. 
Serum protein binding seems independent of serum drug concentrations. 
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3.3.4 Pharmacodynamic analysis 
3.3.4.1 MIC and MBC determination 
The results from the determination of MIC in MHB showed that the two field E. coli isolates were 
sensitive to LEVO. MIC and MBC values are summarized in Table 4. The MIC of LEVO in MHB 
and serum were 0.03 μg/mL and 0.06 µg/mL, respectively. MBC in MHB and serum were 0.03 
and 0.125 μg/mL, respectively. 
 
Table 4. Minimal inhibitory concentrations (MICs), minimal bactericidal concentrations 
(MBCs) for field Escherichia coli isolates and the reference E. coli ATCC 25922 strain. 
E. coli strain 
MIC μg/ml MBC μg/ml 
MHB Serum MHB Serum 
Sensitive E. coli A 0.03 0.06 0.03 0.125 
Sensitive E. coli B 0.03 0.06 0.03 0.125 
E. coli ATCC 25922 0.015 - 0.03 - 
 
3.3.4.2 In vitro bacterial killing curves 
In vitro bacterial activities of LEVO against E. coli has been presented in Figure 18A. The number 
of bacteria in control sample was increased in count of ~5 log10 CFU/mL after 24 h incubation. 
For 1/2 MIC and MIC treatment, the growth of bacteria has been reduced up to 6 h, when a slight 
increasing was visible. The number of bacteria was decreased in count of >3 log10 CFU/mL after 
3 h exposure and it reduced below the limit of detection at 2 MIC. Concentration ranging from 4 





Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
3.3.4.3 Ex vivo bacterial killing curves 
The ex vivo antibacterial activity of LEVO against sensitive field E. coli was determined using 
serum samples collected at different time points (10, 30 min, 1, 4, 6, 10, 24 and 48 h), following 
mean LEVO concentration were 841, 1591, 2135, 981, 651, 329, 137 and 27 ng/mL, respectively. 
The ex vivo time killing curves are presented in Figure 18 B. Ex vivo antibacterial effect of LEVO 
was similar to in vitro time kill curve that indicated LEVO concentration above 4 MIC lead to 
eradication of E. coli after 24 h of incubation. At the lowest plasma concentration sample (48 h), 
of the number of bacteria remained stable in comparison of 3 h incubation time point, however, 
the level of bacteria was increased in amount of control sample after 6 h. All the other tested 
samples, ranging from 10 min to 10 h, demonstrated a high bactericidal effect, that started after 3 
h of incubation and that was maintained for the entire experiment. The samples of 24 h 
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Figure 18. In vitro (A) and ex vivo (B) antibacterial effects of levofloxacin in serum of broilers 
against E. coli after PO administration at 5 mg/kg. 
 
3.3.5 PK/PD integration 
The mean values of in vivo Cmax/MIC, AUC24h/MIC, Cmax/MPC and AUC24h/MPC against E. coli 
were represented in Table 5.  
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After oral administration of LEVO, in vivo Cmax/MIC and AUC24h/MIC obtained against E. coli 
were 32.48 and 261.59 h, respectively. Moreover, the mean values for in vivo Cmax/MPC and 
AUC24h/MPC were 15.59 and 125.56 h, respectively. 
 
Table 5. Indices of PK/PD integration after PO administration of levofloxacin at 5 mg/kg in 
broilers. 
Parameters Units Mean ± SD 
 Cmax/MIC - 32.48 ± 6.37 
 AUC24h/MIC h 261.59 ± 24.41 
 Cmax/MBC - 15.59 ± 3.06 
 AUC24h/MBC h 125.56 ± 11.71 
 
3.3.5.1 PK/PD modelling and optimal dose determination 
The PK/PD indices obtained from Emax model were presented in Table 6. The mean values of ex 
vivo AUC24h/MIC corresponded to bacteriostatic, bactericidal and eradication effects were 18.77, 
24.02 and 36.27 h, respectively. The slope of Emax model was steep with mean N value of 5.21. 
Basing on the obtained ex vivo AUC24h/MIC by PK-PD modelling, the daily optimal dose of LEVO 
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Table 6. Parameters of PK/PD modelling from ex vivo experiment after oral administration of 
levofloxacin at 5 mg/kg in broilers. 
Parameters Units Mean ± SD 
Log10 Emax CFU/mL -6.65 ± 0.18 
Log10 E0 CFU/mL 3.35 ± 0.08 
Log10 Emax-E0 CFU/mL -10.01 ± 0.21 
EC50 h 21.46 ± 6.94 
AUC24h/MIC for bacteriostatic effect h 18.77 ± 0.12 
AUC24h/MIC for bactericidal effect h 24.02 ± 0.28 
AUC24h/MIC for bacterial eradication h 36.27 ± 0.88 
Slope (N) - 5.21 ± 0.83 
E0, difference in bacterial count in control sample between time 0 and 24 h; Emax, difference in bacterial 
count in sample incubated with levofloxacin between time 0 and 24 h, when the detection limit is 
reached; EC50, AUC24h/MIC of drug producing 50% of the maximum antibacterial effect; N, slope of 
the AUC24h/MIC – response curve. 
 
Basing on the obtained ex vivo AUC24h/MIC by PK-PD modelling, the daily optimal dose of LEVO 
was obtained corresponding for bacteriostatic, bactericidal and eradication effects. The MIC90 
values (range from 0.06 to 0.125 µg/mL) of LEVO against E. coli were used from literatures for 
the determination of optimal dose (Hansen and Blondeau, 2005). Optimal doses for the expected 
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Table 7. Predicted optimal daily dose of levofloxacin for PO administration in broilers. 
Expected effects aMIC90: 0.06 µg/mL aMIC90: 0.125 µg/mL 
Dose for bacteriostatic effect 1.1 mg/kg 2.2 mg/kg 
Dose for bactericidal effect 1.4 mg/kg 2.9 mg/kg 
Dose for eradication 2.1 mg/kg 4.3 mg/kg 
a MIC90 values from a literature (Hansen & Blondeau, 2005). 
 
3.4 Discussion and Conclusion 
It has been widely recognized that an inappropriate usage of antibiotics, like as overuse and misuse 
is one of the risk factor for both emergence of resistance and therapeutic failure. Thus, the 
appropriate dosage should be designed, not only to maximize clinical efficacy, but also to 
minimize the emergence of resistance for target animal species (Schentag, 2000; Dagan et al., 
2001; Toutain et al., 2002). The PK/PD approach has been considered as a demonstrable tool in 
the design of optimal dosage strategies. In addition, PK/PD modelling of time–kill curves has the 
advantage of describing the PD effect by parameters, which represent the potency and efficacy of 
drug. Data on the PK/PD of LEVO in poultry are limited, and, in authors’ knowledge, this is the 
first complete study that considers PK/PD of LEVO in broilers. 
After IV and PO administration of LEVO in broilers, the mean values of half-life for IV and PO 
group were 6.93 and 8.09 h, respectively, which are longer than those reported in sheep (Patel et 
al., 2012), camels (Goudah, 2009), goats (Goudah et al., 2009) and cattle calves (Kumar et al., 
2012), but shorter than those in cats (Albarellos et al., 2005). These data indicate that LEVO shows 
some difference in elimination rate among animal species. However, these findings were not 
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at 10 mg/kg in broilers. These differences may potentially be explained by experimental 
discrepancies of dosage, age, breed and number of animals between the two studies. 
The apparent volume of distribution at steady state (Vdss) was 2881 mL/kg in broilers indicating 
a relatively wide distribution and it was higher than those reported in sheep (Patel et al., 2012), 
camels (Goudah, 2009), goats (Goudah et al., 2009) and cats (Albarellos et al., 2005). In addition, 
it was consistent with that reported in broilers (Varia et al., 2009). LEVO is eliminated primarily 
by the kidney with the involvement of both glomerular filtration and tubular secretion (Fish & 
Chow, 1997). The CL (mean value; 381.17 mL/h/kg) in broilers was similar to those observed in 
cattle calves (Kumar et al., 2012), sheep (Patel et al., 2012) and camels (Goudah, 2009). 
The absolute bioavailability of LEVO in broilers after PO administration was almost complete 
with mean %F value (123.25 %) suggesting the excellent absorption of LEVO in broilers. 
However, the variation of bioavailabilities has been found among animal species. This value was 
similar to that measured in camels (94%; Goudah, 2009), but higher than those observed in calves 
(62%, Kumar et al., 2012; 57%, Dumka & Srivastava, 2006; 2007), and cats (71%; Albarellos et 
al., 2005). 
Following PO administration of LEVO at the dose of 5 mg/kg revealed drug concentration in liver 
was 6.57±1.74 μg/g after 1 h and 0.14±0.01 μg/g after 48 h respectively, whereas in muscles the 
concentration was 0.94±0.07 μg/g after 1 h and 0.04±0.01 μg/g after 48 h respectively. This 
persistence of drug in tissue supports the wide value for Vss found in this investigation. The levels 
of LEVO in liver and kidney were higher (4-5 folds) than those measured in muscle and lung 1 h 
after administration. This might suggest a specific LEVO affinity for these two clearing organs. 
The PK/PD approach allows to determine the optimal dosage on the basis of the microbiological 
susceptibility and the variation of the disposition kinetics (Hyatt et al., 1995; Sanchez- Recio et 




Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
of PKs are the area under the plasma concentration curve (AUC), the maximum plasma 
concentration (Cmax) and the duration of plasma concentration exceeding the MIC (T>MIC) (Hyatt 
et al., 1995). The key PD parameter is the minimum inhibitory concentration (MIC) (Hyatt et al., 
1995). Although the methods for MIC are standardized and reproducible (CLSI, 2009), the results 
of this method may be influenced by many technical factors (inoculum size, incubation times, 
medium content, etc) (Hyatt et al., 1995). Significant difference of MIC or MBC values both in 
broth and serum have been found in many investigations (Hyatt et al., 1995; Aliabadi & Lees, 
2001). In the present investigation, MIC and MBC of LEVO against E. coli were determined in 
broth and serum of broilers to overcome this limitation. MIC (0.03MHB–0.06 serum μg/mL) and MBC 
(0.03 MHB –0.125 serum μg/mL) were significantly different in both matrices. This result indicates 
that the serum inhibitory activity was reduced and that corresponds with previous data reported on 
the decreased antimicrobial effects of most fluoroquinolones in serum (two- to four-fold higher 
MICs) (Aliabadi et al., 2003a; Aliabadi et al., 2003b; Haritova et al., 2004). This result may be 
accounted for moderate protein binding (38%, Fish & Chow, 1997 and in buffalo (19%, Ram et 
al., 2008). The protein binding of LEVO in broilers determined in this investigation was in 
between those previously reported, but still in the same range.  
Data from the time killing curve indicates that LEVO showed concentration-dependent killing 
pattern against E. coli. For E. coli, LEVO produced an in vitro antibacterial activity with low 
multiples (2- and 4-) of MIC in serum. The bactericidal activity rapidly manifested within 3–6 h 
of incubation, followed by eradication with 4MIC at 3 h. The elimination of bacteria was 
maintained up to 24 h of incubation (where drug concentration > 2 MIC). Ex vivo antibacterial 
activity was consistent with in vitro time killing curve data that indicated LEVO concentrations ≥ 
2 MIC lead to eradication of E. coli. To the author's knowledge, this is the first paper reporting 
this comparison. According to Hyatt et al. (1995), in quantitative terms the PK/PD parameters 
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currently available, are AUC24/MIC, Cmax/MIC and T N MIC. AUC24/MIC and Cmax//MIC are the 
best predictor of efficacy correlating with concentration-dependent antibiotics (Craig, 1993; 
McKellar et al., 2004). It has been widely proposed that dosage regimens which produce high 
PK/PD parameters such as AUC24/MIC > 125 and Cmax/MIC > 10, are more likely to be successful 
and less likely to be associated with emergence of resistance (Forrest et al., 1993; Schentag, 2000). 
However, more recent studies suggested that these values might be overestimated and should be 
lowered in veterinary medicine (Papich, 2014). The calculated mean Cmax//MIC and AUC24 h/MIC 
for LEVO in this study were 32 and 262, respectively. According to the concept outlined above, 
the dose of 5mg/kg/day PO in broilers seems to be effective for the treatment of colibacillosis. In 
addition, in vitro MIC method using artificial growth media are limited by the lack of various host 
factors such as their immune function. To address this limitation, integration of PD to PK in an ex 
vivo model was attempted in this study. The ex vivo AUC24/MIC parameters were utilised for this 
integration using the sigmoid Emax model with the reduction in bacterial numbers after 24 h of 
incubation. The lowest effective ex vivo AUC24/MICs, corresponding to bacteriostatic, 
bactericidal activity and eradication of the bacteria, were determined for serum. The mean values 
of ex vivo AUC24/MIC corresponding to bacteriostatic, bactericidal and eradication effects were 
18.77, 24.02 and 36.27 h, respectively. The optimal dosages corresponding to bacteriostatic, 
bactericidal activity and eradication of the bacteria were predicted by using the ex vivo 
AUC24/MIC. The calculated optimal doses for bacteriostatic, bactericidal activity and eradication 
were 1.1, 1.4 and 2.1 mg/kg, respectively, considering MIC90 of 0.06 μg/ml. However, using 
recently reported MIC90 (0.125 μg/ml) of E. coli the predicted doses were 2.2, 2.9 and 4.3 
mg/kg/day PO, respectively.  
In conclusion, this is the first study to access the PK/PD relationship of LEVO in broilers. PK/PD 
indices against E. coli were investigated in an ex vivo model. The data presented would suggest 
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4. Determination and validation of two analytical methods for quantification of 
tulathromycin in plasma goats. Pharmacokinetic study of tulathromycin in 
lactating goats. 
 
Macrolides (erythromycin, tylosin, spiramycin, and tilmicosin) are a class of antibiotics approved 
for the use in livestock. Typically, repeated administrations of these drugs over several days are 
required to achieve therapeutic efficacy, but single administration therapy is desirable for livestock 
producers who wish to minimize animal handling and maximize compliance (Gàler et al., 2004).  
Tulathromycin (TU) is a novel triamilide belonging to the macrolides class of antibiotics used for 
the treatment of respiratory diseases in cattle and swine providing high clinical efficacy after a 
single parenteral administration at 2.5 mg/kg. 
Nowadays, though domestic goats are present as a worldwide population in numbers large enough 
to confer a status of major species, these animals are still considered as a minor species by the 
regulatory agencies in Europe and the USA (Toutain et al., 2010). Due to the lower number of 
goats compared to the other livestock species their health issues cannot be addressed with EMA 
or FDA-approved medications. Consequently, many drugs are administered to goats in an extra-
label manner with no scientific information on drug behaviour, potential toxicity, and adequate 
withdrawal periods for drug removal from products marketed for human consumption (Clothier, 
2010). 
Bacterial pneumonia is a frequent health problem in small ruminants. Mannheimia haemolytica, 
Bibersteinia (Pasteurella) trehalosi, Pasteurella multocida, and Mycoplasma spp. are all 
commensals of the upper respiratory tract in ruminants that contribute to severe pneumonia upon 
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indications of TU including only beef and non-lactating dairy cattle for the treatment of bovine 
respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus 
somni (Haemophilus somnus) and Mycoplasma bovis, infectious bovine keratoconjunctivitis 
associated with Moraxella bovis and for the control of respiratory disease in cattle at high risk of 
developing bovine respiratory disease associated with Mannheimia haemolytica, P. multocida, H. 
somni and M. bovis. In addition, TU is registered in the USA for the treatment of interdigital 
necrobacillosis associated with Fusobacterium necrophorum and Porphyromonas levii. The FDA 
and EMA approved TU also for swine where the drug is recommended for the treatment of 
respiratory conditions associated with Actinobacillus pleuropneumoniae, P. multocida, Bordetella 
bronchiseptica, and Haemophilus parasuis (Villarino et al., 2013a). 
In order to characterize drug disposition of TU in different biological matrices and its relationship 
to efficacy, an accurate, precise and robust analytical method is requested. TU is manufactured as 
a single isomer or parent compound, designated CP472,295. This molecule equilibrates in solution 
into in 9:1 mixture of two TU isoforms, designated CP-472,295 and 547,272, respectively. A 
recent method for TU evaluation has been published by Gáler et al. (2004). It quantifies the levels 
of the parent compound CP-472,295 (fragment) in plasma or lung tissue samples using a detection 
via electrospray ionization and tandem mass spectrometry. Moreover, EMA and FDA approved 
the common fragment or marker residue (CP-60,300) for the two different isoforms CP-472,295 
and 547,272. This marker residue was shown to account for between 78 and 95% of all residues 
in another animal (sheep) where the drug is usually used in off-label manner. Based on the residue 
depletion data, distribution of marker residue between target tissue and ratios of marker to total 
residues, and taking into account the toxicological ADI of 3000 µg/person, the MRL values for 
muscle, liver and fat in ovines should be 450 µg/kg for muscle, 250 µg/kg for fat, 5400 µg/kg for 
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In line with Article 5 of Regulation (EC) No 470/2009 the Committee for Medicinal Products for 
Veterinary Use (CVMP) has allowed the extrapolation of the MRL for TU in other food producing 
animals. Taking into account the current scientific knowledge the recommendations on 
extrapolation are justified as follows: existing data indicates that the pattern of metabolites seen in 
rats, dogs, cattle, pigs and sheep are similar. Open available information indicates that the marker 
residue established for sheep is also present in goat tissues. Although it was not specifically 
demonstrated, the analytical method for monitoring of residues in sheep tissues is expected to be 
applicable for monitoring of residues in goat tissues. Concerning milk residue, no data are 
available that would allow conclusions to be drawn on the appropriate marker residue or marker 
to total residues ratio to use in milk. Milk is consumed on a regular basis and in large quantities 
and consequently data on residues in this commodity are considered necessary in order to allow 
adequate evaluation of the risk of a safety consume posed by residues in milk. Investigation on the 
use of TU in dairy cows showed that TU is extensively partitioned into milk. Consequentially, 
basing on the required 1.5 L consumption factor, the use of this drug in dairy cows would not be 
practicable. Moreover, at this moment, no established milk tolerance (MRLs) and approved 
analytical method for monitoring of residues in milk are available for evaluation of TU 
concentration (EMA/CVMP/131462/2014). Therefore, any detectable residues are considered 
violative, and it is important that the withdrawal time of TU concentration in milk falls below the 
analytical detection limit to ensure food safety (Lin et al., 2016). Microbiological assay was used 
to quantify TU residues in milk but milk samples were collected only 19 days post-treatment 
(Amer et al., 2012). Moreover, a sensitive analytical method performed by Grismer et al. (2013) 
was used to quantify the CP-60,300 fragment in milk. In this study, at the last sampling (45 days 
post-treatment), milk CP-60,300 residues were at or above the LOD (1.8 ng/mL) for five goats and 




Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
estimated that after 90 days (10 times longer than terminal half-life) residues should not be 
detectable in milk.  
 
4.1 Aim of the study 
The aim of the present study was fourfold: 
-To develop a new analytical method for the determination and quantification of TU by the HPLC-
FL. 
-To develop a new analytical method for the determination and quantification of TU by the 
HPLC/MS-MS. 
-To evaluate its PK in lactating goats before lactating period (IV and SC administrations) and 
during lactation (IV administration) of TU at labelled dose for cattle and swine (2.5 mg/kg).  
-To develop a new analytical method for the determination and quantification of the TU (CP-
60,300) in milk goats by the HPLC/MS-MS. 
 
4.2 Material and methods 
4.2.1 Development of a new analytical method for the determination and quantification of TU by 
the HPLC-FL. 
The analytical method was performed at the University of Pisa, Department of Veterinary 
Sciences, Italy. 
4.2.1.1 Chemicals, reagents and solutions 
The pure compound of TU and roxithromycin used as internal standard (IS) were provided by 
Toronto Chemical Research Inc (Brisbare road, Toronto, ON, Canada). Acetonitrile (ACN, LC-
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potassium dihydrogenphosphate (KH2PO4) were purchased from Sigma-Aldrich (Saint Louis, 
MO, USA). Deionised water was produced by a Milli-Q Milli-pore Water System (Millipore, MA, 
USA). All other reagents and materials were of analytical grade and supplied from commercial 
sources. The LC mobile phase were filtered through 0.2 µm cellulose acetate membrane filters 
(Sartorius Stedim Biotech S.A., Aubagne Cedex, France) with a solvent filtration apparatus.  
Singular stock solutions of TU and IS in acetonitrile (ACN) were prepared, at a concentration of 
1000 µg/mL, using volumetric flasks and diluted to prepare 6 concentrations at 100, 10, 5, 1, 0.5, 
and 0.1 µg/mL. 
A phosphate buffer solution was prepared for the mobile phase using potassium 
dihydrogenphosphate 50 mM, 500 µL of triethanolamine (TEA) and the pH modified to 7.5 with 
potassium hydroxide 10%. A phosphate buffer solution was prepared for the extraction method 
using potassium dihydrogenphosphate 0.1M and the pH was modified to 7.5 with phosphoric acid. 
4.2.1.2 Chromatographic conditions 
The HPLC system was an LC Jasco (Como, Italy) consisting of quaternary gradient system (PU 
980) and an in line multilambda fluorescence detector (FP 1520). The chromatographic separation 
assay was performed with a Phenomenex synergy polar analytical column (150 mm × 4.6 mm 
inner diameter, 4 µ particle size [Phenomenex, Bologna, Italy]) preceded by a security guard 
column with the same stationary phase (Phenomenex, Bologna, Italy). The system was maintained 
at 25◦C. The mobile phase consisted of ACN: phosphate buffer solution (50 mM, pH 7.5) at a flow 
rate of 2 mL/min. Excitation and emission wavelengths were set at 260 and 315 nm, respectively. 
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Table 8. HPLC-FL pump program. 
Time range  
(min) 








4.2.1.3 Sample preparation 
Several high-performance liquid chromatography methods for determination of macrolides are 
reported in literature. Most of them required electrochemical detection due to the insensitivity of 
the macrolides with UV and FL detection. Anyway, many studies are present in the literature 
describing analytical methods for the determination with fluorescence detection of different 
macrolides (erythromycin, azithromycin, roxithromycin, clarithromycin) using a derivatization 
method (Toran˜o & Guchelaar, 1998; Bahrami et al., 2005). No study concerning the 
derivatization of TU and its quantification with the HPLC with fluorescence detector is present in 
the literature. In the present study, TU derivatization method and its extraction from plasma were 
based on a previous study reported by Toran˜o & Guchelaar, (1998) and Bahrami et al., (2005) 
with slight modifications. The reaction of derivatization was performed using 9-
fluorenylmethyloxycarbonyl-chloride (FMOC-Cl) optimized at the concentration of 1000 µg/ml 
diluted in ACN. The reaction time, the proportion of acetonitrile–water, the pH and temperature 
of solution were varied around the expected optimal values. A 100 μl aliquot of blank plasma (drug 
free plasma from goats) was spiked with 100 μL of TU at different concentrations (10, 5, 1, 0.5, 
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the sample solution. After shaking for 15 min, the solution was centrifuged for 10 min at 3500 g. 
The organic layer was transferred to the dry disposable glass tube and evaporated at 40° C under 
a flow of nitrogen. The residue was dissolved in 100 μl of ACN and 100 μl of phosphate buffer 
0.1 M at pH 7.5 was added. The sample was vortexed again (30 sec), and finally 100 μl of FMOC-
Cl (1000 μg/mL) was added. The sample was vortexed (30 sec) and incubated in a water-bath of 
50° C for 40 min. After derivatization 200 μl of mobile phase solution (ACN: phosphate buffer 50 
mM ph 7.5, 60:40) was added and the sample was injected into the HPLC-FL. 
 
4.2.2 Development of a new analytical method for the determination and quantification of TU by 
the HPLC/MS-MS. 
The analytical method was performed at the University of Pisa, Department of Surgical, 
Medical, Molecular and Critical Area Pathology, Italy. 
4.2.2.1 Chemicals, reagents and solutions 
The pure compound of TU and Azithromycin (AZI), used as internal standard (IS) were provided 
by Toronto Chemical research Inc (Brisbare road, Toronto, ON, Canada). Acetonitrile (LC-MS 
grade), ultra-pure water (LC-MS grade), ammonium acetate solution 7.5M (CH3COONH4, for 
molecular biology), sodium chloride (NaCl), and sodium carbonate (Na2CO3) were purchased 
from Sigma-Aldrich (Saint Louis, MO, USA). Singular stock solutions of TU and IS in ACN (100 
µg/ml) prepared by serial dilution in drug free plasma, were diluted to prepare a 6-point calibration 
curve at the following concentrations 5 (L1), 25 (L2), 50 (L3), 250 (L4), 500 (L5), and 1000 (L6) 
ng/ml), and stored at -20°C and used as standard stock solutions. Calibration standards (200 µl 
each) were added with DPS (Daily Precipitation Solution) and treated like the samples.  
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The procedure of TU determination and extraction from plasma were based on that previously 
reported by Toutain et al., (2017) with slight modifications. TU and IS analytes were determined 
by an instrument consisting in an AB Sciex API 4000 triple quadrupole mass spectrometer 
(Concord, ON, Canada), equipped with an ESI source, a quaternary HPLC pump (Series 200, 
Perkin Elmer, Boston, MA, USA), and an Agilent 1290 Infinity UHPLC system (Santa Clara, CA, 
USA), constituted by an autosampler outfitted with peltier tray, a binary pump, and a column oven. 
A ten port switching valve (Valco Instruments Co. Inc., Huston, TX, USA) was used as a divert 
valve. Chromatographic separation was performed by a Waters (Torrance, CA, USA) Acquity 
UPLC BEH C18 1.7 µm, 2.1 x 50 mm HPLC column protected by a BEH C18 1.7 µm security 
guard cartridge. Data acquisition and system control were carried out by an AB Sciex Analyst® 
version 1.6.3 software, while data processing by an AB Sciex Multiquant® version 3.0.2 software. 
Binary pump, quaternary pump, and divert valve were properly set in order to discard both head 
and tail of the HPLC runs. This granted an adequate robustness to the analytical method, 
preventing progressive reduction of instrumental sensitivity. The HPLC separation was performed 
under the gradient conditions shown in Table 9, maintaining the column temperature at 40 °C. The 
eluents were: solvent A: ACN and solvent B: mixture water containing CH3COONH4 20 mM pH 
4. The injection volume was 10 µl for samples, and calibrators. The divert valve was set in order 
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Table 9. HPLC/MS-MS pumps program. 
                    
 HPLC Quaternary Pump  HPLC Binary Pump 
                    






















                    
                    
0  0.00   100  50 50   0.00  250  5   95  
1  13.5   100  50 50   1.00  250  5   95  
2           8.00  250  95   5  
4           11.1  250  95   5  
5           11.5  250  5   95  
6           13.5  250  5   95  
                    
                    
Solvent A is acetonitrile; solvent B is water containing CH3COONH4 20mM pH 4 (V%) 
 
The MS method was based on positive ion mode selected reaction monitoring (SRM). Using 
optimized declustering potential (DPs), collision energies (CEs), and collision exit potentials 
(CXPs), two transitions were monitored for each compound, the more intense which, was used as 
a quantifier (Q), while the other one as a qualifier (q). These parameters are listed in Table 10. 
Further operative parameters were set as follows: ionSpray voltage (NC), 5.0 KV; gas source 1 
(GS1) zero air, 45; source temperature (TEM), 550°C; entrance potential (EP), 10 V; IQ1 lens 
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Table 10. Mass Spectrometry operative parameters 
        
        
 
Analyte 
  Operative Parameters 
  
SRM transitions 
    
    
  DP CE CXP 
        
        
 
Tulathromycin 
 806.6 → 158.1 (q)  
136.6 
54.4 13.3 
  806.6 → 577.3 (Q)  32.5 16.7 
        
 
Azithromycin 
 749.6 → 591.5 (q)  
130 
40.2 8.5 
  749.6 → 573.2 (Q)  46.4 9 
        
        
 
 
The described method was re-validated in terms of linearity, limit of detection (LOD), limit of 
quantification (LOQ), recovery, specificity, stability, precision and accuracy according to 
international guidelines on the bioanalytical method validation (Anonymus, 2011). The calibration 
curve was based on analyte/IS peak area ratios. Correlation coefficient for the calibration curve 
was r2>0.99. Within-run and between-run accuracy and precision were assessed on quality control 
samples (QC samples) and determined by replicate analyses using 3 determinations of different 
concentration levels: LOQ (L1), low QC (L2 and L3), medium QC (L4) and high QC (L5 and L6). 
Stability studies were performed to ensure good reproducibility of the method. Stock solution of 
the analyte and IS (1 μg/mL) and high and low QC samples were tested for short-term room 
temperature conditions, long term storage conditions (−20 °C) and freeze–thaw stability. Short-
term stability determinations were obtained by thawing the QC samples and keeping them at room 
temperature for 24 h, whereas long-term stability was assessed by storing the samples for a period 





Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
4.2.2.3 Animal experiment for the analytical validation 
The applicability of this method has been verified in two healthy lactating goats. The study 
protocol was approved by both the University of Pisa’s ethics committee for animal welfare 
(OPBA) and the Italian Ministry of Health (462/2017 PR). TU was administered by IV route at 
labelled dose for cattle and swine (Draxxin® 100 mg/mL, 2.5 mg/kg b.w.). The commercial drug 
was diluted to 25 mg⁄mL with the double-distilled water containing a 50% propylene glycol vehicle 
and monothioglycerol (5 mg⁄ mL). The 1 mL of solution contained 25 mg of TU with pH value of 
7.0, which was adjusted under sterile conditions prior to drug administration (Wang et al., 2011). 
The blood (5 mL) was collected via indwelling catheter previously inserted in the left jugular vein, 
at assigned times (0, 15, 30, min and 1, 2, 4, 6, 8, 10, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 
h). After centrifugation at 400xg for 10 min plasma samples were separated and stored at -20 °C 
until use within 30 days from collection. 
4.2.2.4 Sample preparation  
The procedure of TU extraction from plasma was based on that previously reported by Gáler et al. 
(2004) with slight modifications. Aliquots (200 µl) of plasma were added to 100 µl of a Na2CO3 
saturated solution and 100 µl of a freshly prepared DPS containing ACN and IS (25 ng/ml). The 
obtained suspensions were vortexed (15 min) and centrifuged (18,620 x g, 15 min). Each sample 
was added with 700 µl of acetonitrile and 50 mg of NaCl, then they were vortexed (15 min) and 
centrifuged (18,620 x g, 15 min) again. Aliquots of 600 µl of organic supernatants were then 
collected and dried under a gentle stream of nitrogen at 40° C. The dried residues were 
reconstituted with 100 µl of a mixture of the HPLC eluents, solvent A and solvent B (20/80; V/V), 
and the reconstituted matters were vortexed (15 min) and 10 µl of the obtained solutions was 
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4.2.2.5 Statistical analysis and pharmacokinetic evaluation 
The statistical analyses were evaluated using the Student’s t-test. The results were presented as 
mean ± standard deviation (SD). In all the experiments, differences were considered significant if 
the associated probability level (P) was lower than 0.05. The pharmacokinetic calculations were 
carried out by WinNonlin v 5.3.1 (Pharsight Corp, Sunnyvale, CA, USA), using the standard non-
compartmental analysis. 
4.2.3 PK study in lactating goats 
4.2.3.1 Animal experiment 
The animal experiment was approved by the animal welfare ethics committee of the University 
of Lublin (authorization # 62014) and carried out in accordance with the European law 
(2010/63/UE). The study was split in 2 periods (not pregnant vs lactating goat). In the first 
period, first phase, 6 healthy not pregnant goats were divided randomly in two groups A (n=3) 
and B (n=3) according to a single-dose, two-treatment, two-phase, paired, cross-over design (2x2 
Latin-square). TU was administered by IV and SC routes at the dose of 2.5 mg/kg b.w. The 
washout period was 2 months due to the expected long half-life of elimination of TU (Amer et 
al., 2012; Grismer et al., 2013). Blood samples (5mL) were collected from the right jugular vein 
of each goat immediately before medication and at intervals of 5, 15, 30 min, 1, 2, 4, 6, 8, 10, 24, 
48, 72, 96, 120, 144, 168, 192, 216 and 240 h (up to 10 days).  
During the second PK period, TU was administered by IV administration at the dose of 2.5 
mg/kg to the same 6 goats during the lactation period. The drug was administered on the day in 
milk (DIM), almost 1 week after parturition. Blood samples were collected after milk sample 
collections following the same time schedules of the previous period. Milk sampling for residue 
detection of TU were collected prior and at 30 min, 1, 2, 4, 6, 8, 10, 24 h after drug 
administration (day 1), and once a day for days 2-90. During the first day of sampling, milk was 




Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
were totally milked from both udders into separate vials. Milk samples were stored at -20° C 
within 2 h of samples collection, until analysis for the determination of TU concentration. 
4.2.3.2 Pharmacokinetic analysis 
Pharmacokinetic parameters for IV and SC administration were determined individually as a non-
compartmental model using WinNonlin 5.3.1 software (Pharsight Corp, Sunnyvale, CA, USA).  
The SC bioavailability (F) was calculated as (Eq. 9): 
 





4.2.3.3 Statistical analysis and pharmacokinetic evaluation 
The statistical analyses were evaluated using the Student’s t-test. The results were presented as 
mean ± standard deviation (SD). In all the experiments, differences were considered significant if 
the associated probability level (P) was lower than 0.05.The pharmacokinetic calculations were 




4.3.1 Development of a new analytical method for the determination and quantification of TU by 
the HPLC-FL. 
4.3.1.1 Optimization of the analytical method 
In the present study, to optimize the analytical method, different parameters were tested. 
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detector showed the values of 260 and 315 nm as the optimal excitation and emission wavelengths 
for the two compounds, respectively. Three different columns were tested: Luna C18 (250 mm × 
4.6 mm inner diameter, 5 µ particle size), Luna C18 (150 mm × 4.6 mm inner diameter, 5 µ particle 
size) and Phenomenex synergy polar (150 mm × 4.6 mm, 4 µ particle size). The latter column 
presented the better chromatographic separation between TU, IS and matrix peaks. Two 
compounds (roxithromycin, and azithromycin) with amenable chemical features were evaluated 
as ISs. Among these, roxithromycin was found to be the best candidate with an excellent resolution 
and a suitable retention time, providing the shortest chromatographic course and with peaks well 
distinct and separated from both the TU peak and matrix interferences (Figure 19). On the other 
hand, azithromycin, the most similar to TU in chemical and physical characteristics, showed partial 
overlap with TU. Two mobile phases were preliminarily tested, the ACN:ammonium acetate 
buffer and ACN:phosphate buffer at different pH and buffer concentrations. The latter mobile 
phase with a 2.0 mL/min flow, rate was found to optimally provide separation between TU, IS and 
matrix interference peaks in short chromatographic run. A range of buffer pH (5.0, 6.0, 7.0 and 
7.5) were tested to optimize the chromatographic separation. The retention time of TU and IS were 
influenced by different pH. A pH value of 7.5 provided the best separation between the TU, IS and 
matrix peaks.  
Concerning the extraction method, solvents such as AcOEt, CH2Cl2, Et2O and ACN were 
examined. The ACN was selected as the most suitable organic solvent in terms of analyte 
extraction and minimization of matrix components. Finally, different concentrations of FMOC-Cl 





Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
 
Figure 19. Chromatographic curve from goats control plasma fortified with TU 
100 μg/mL and IS 1 μg/mL). 
 
4.3.2 Development of a new analytical method for the determination and quantification of 
TU by the HPLC-MS/MS. 
4.3.2.1 Optimization of the analytical method 
As mentioned in paragraph 4.2.2.2. the procedure of TU determination from plasma was based on 
that previously reported by Toutain et al., (2017) with slight modifications. To optimize the 
analytical method, different parameters were tested. Two compounds (roxithromycin, and 
azithromycin) with amenable chemical features were evaluated as ISs. Among these, azithromycin 
was found to be the best candidate for similar chemical and physical characteristics to TU, an 
excellent resolution and a suitable retention time (4.30 min.), providing the shortest 
chromatographic course and good baseline separation of them from each (Figure 20).  
IS (1 μg/mL) 
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Figure 20. HPLC-MS extracted ion chromatogram. It was acquired from a 
real sample and is relative to the ions at m/z 806.6 and 749.6 Da. The peaks 
from TU and IS, are clearly shown at 4.30 min and 4.77 min, respectively. 
 
By injecting standard solutions into a mass spectrometer equipped with an electrospray ionization 
source, TU and IS were detected by monitoring the following Selected reaction Monitoring (SRM) 
transitions: 806.6 > 577.3 Da (quantifier) and 806.6 > 158.1 Da (qualifier) for TU and 749.6 > 
591.5 Da (quantifier) and 749.6 > 591.5 Da (qualifier) for IS. Instrumental parameters were 
optimized in order to maximize signal of those transitions. No endogenous or extraneous 
interfering peaks were observed. Concerning the mobile phase, the ACN:ammonium acetate buffer 
was preliminarily tested at different pH (4, 4.5, 5, 6 and 7) and buffer concentrations (20, 50, 100 
mM). The ammonium acetate phase at 20 mM and pH 4 was found to provide optimally separation 
between TU, IS and matrix interference peaks in short chromatographic run. The method exhibited 
a good linear response for the concentration range of 5-1000 ng/mL. Intra-day and inter-day 
precisions were lower than 15% and the accuracy was ranging from 103 to 105%. The limit of 
quantification (LOQ) was 5 ng/mL with a precision of 9% and an accuracy of 107%. 
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Concerning the extraction method, differently from studies present in the literature where the solid 
phase extraction method (SPE) was commonly used for the extraction of TU, a liquid/liquid 
extraction method has been developed. Different solvents such as AcOEt, CH2Cl2, ACN and 
different pH solutions (chloridric acid and Na2CO3 saturated) were tested in terms of recovery and 
selectivity. The ACN with Na2CO3 saturated were selected as the most suitable solutions in terms 
of analyte extraction efficiency and minimization of matrix components, with a recovery for TU 
in a range of 89-95% and for IS in a range of 87-93%. The processed extracts of TU were stable 
in the auto-sampler at room temperature for at least 24 h.  
4.3.2.2 Animal experiment for the analytical validation 
The applicability of this method has been verified by determining TU in plasma of two healthy 
goats after single IV administration with 2.5 mg/kg of Draxxin®. (Figure 21).  
 
  
Figure 21. Mean plasma concentration vs. time curve of TU after IV 
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The described method allowed monitoring of the concentration vs. time curves of the analyte and 
the calculation of the basic pharmacokinetic parameters (Table 11). 
 
Table 11. Pharmacokinetic parameters of TU after IV administration at 2.5 
mg/kg in lactating goats 
       
          IV   
  
Parameter
s   Units   Mean   SD   
  R2       0.97 ± 0.08   
  λz   1/h   0.01105 ± 0.00078   
  HLλz   h   62.81 ± 4.31   
  C0   ng/mL   3255 ± 379   
  AUClast   h*ng/mL   18313 ± 757   
  AUC0-∞   h*ng/mL   19649 ± 559.18   
  CL   mL/h/kg   127.29 ± 3.62   
  MRT0-∞   h   81.83 ± 2.6   
  Vss   mL/kg   10421 ± 639   
                  
λZ, first-order rate constant; HLλZ, half-life of the terminal portion of the curve; C0, 
concentration at time 0; AUClast, area under the curve from 0 to the last; AUC0-∞, 
area under the curve from 0 to infinit; Vss, volume of distribution at steady state; 
CL, body clearance during the elimination phase; MRT, mean residence time; F. 
a, significant difference between each treatment group (P<0.05). 
 
4.3.3 PK study in lactating goats 
No adverse effects were observed during the experiment.  
Following the first period of the study, the plasma concentration vs. time curve of the IV and SC 
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Figure 22. Mean plasma concentration vs. time curve of TU after IV (——) and SC 
(--●--) administration at 2.5 mg/kg in lactating goats. Bars represent the SD. 
 
TU concentration for IV and SC were detectable in the plasma up to 240 h. PK parameters of TU 




























Table 12. Pharmacokinetic parameters of TU after IV and SC administration at 2.5 mg/kg in lactating goats. 
                      
        IV   SC 
Parameters   Units   Mean   SD   Mean   SD 
R2       0.97 ± 0.08   0.98 ± 0.02 
λz   1/h   0.01213 ± 0.00264   0.01217 ± 0.00206 
HLλz   h   58.83 ± 1.40   58.21 ± 1.78 
Tmax   h   / ± /   0.63 ± 0.08 
Cmax   ng/mL   / ± /   520.71 ± 75.51 
C0   ng/mL   3035 ± 370   / ± / 
AUClast   h*ng/mL   17685 ± 752   18383 ± 679 
AUC0-∞   h*ng/mL   18757 ± 743   19684 ± 627 
VD   mL/kg   / ± /   10668 ± 1562 
CL   mL/h/kg   136.47 ± 25.09   127.11 ± 4.07 
MRT0-∞   h   78.24 ± 5.15   90.94 ± 6.31 
Vss   mL/kg   10692 ± 2192   / ± / 
F   %           104.9 ± 1.2 
                      
λZ, first-order rate constant; HLλZ, half-life of the terminal portion of the curve; Tmax, time at the maximum drug concentration; Cmax, maximum plasma drug concentration; C0, concentration at time 
0; AUC0-24, area under the curve from 0 to the last; Vss, volume of distribution at steady state; V/F, volume of distribution during the elimination phase; CL/F, body clearance during the elimination 
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After a SC administration, TU showed fast absorption with the mean Tmax value of 0.63 h and a 
slow drug elimination. The mean values of HLλZ for IV and SC were 58.83 and 58.21 h, 
respectively. The bioavailability for SC administration was complete with a mean value of 104.9 
%. 
Following the second period of the study, Figure 23 show the plasma concentration vs. time curves 
of TU at 2.5 mg/kg administered by IV injection in lactating goats during two different 
physiological conditions: non pregnant(-○-) and lactating (-▲-) conditions. 
 
 
Figure 23. Mean plasma concentration vs. time curve of TU after IV 
administration during not pregnant (——) and lactating (—▲—) conditions at 
2.5 mg/kg in goats. Bars represent the SD. 
 
Pharmacokinetic parameters of TU after IV administration during lactation condition are 
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Table 13. Pharmacokinetic parameters of TU after IV administration 
at 2.5 mg/kg in lactating goats during lactation condition. 
              
        IV 
Parameters   Units   Mean ± SD 
R2       0.97 ± 0.04 
λz   1/h   0.00847 ± 0.00354 
HLλz   h   67.15 ± 11.53 
C0   ng/mL   2652 ± 282 
AUClast   h*ng/mL   18905 ± 2608 
AUC0-∞   h*ng/mL   21607 ± 2476 
CL   mL/h/kg   117.08 ± 14.40 
MRT0-∞   h   88.35 ± 4.46 
Vss   mL/kg   12784 ± 3944 
              
λZ, first-order rate constant; HLλZ, half-life of the terminal portion of the curve; C0, 
concentration at time 0; AUClast, area under the curve from 0 to the last; AUC0-∞, 
area under the curve from 0 to infinit; Vss, volume of distribution at steady state; 
CL, body clearance during the elimination phase; MRT, mean residence time; F. 
a, significant difference between each treatment group (P<0.05). 
 
During lactating condition, PK parameter resulted not significantly different from PK parameters 
obtained during not pregnant condition. HLλz, Vss and CL resulted higher but not significantly 
different from the first period of the study.  
Concerning TU residues in milk, the animal experiment was completed, milk was collected up to 
90 days after administration of the drug, but it was not still possible to determine the CP-3600 
fragment of TU due to the analytical problems on the determination and validation of an 
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4.4 Discussion and conclusion 
Currently there are limited antimicrobials available for treatments of bacterial infections in goats, 
despite this animal species is often affected by infection diseases. Pharmacokinetic data on 
potential drugs is critical to ensure effective treatment and safe food for human consumption.  
TU has been showed to be very effective against major respiratory pathogens of both cattle and 
swine. Safety profile of TU in caprine species has been found good (Washburn et al. 2007). 
Indeed, adult goats were treated with 25 mg/kg of TU which is ten times the labeled dose (2.5 
mg/kg) for cattle and swine and observed for signs of adverse reactions. Observations on 
physical condition, clinical pathology parameters and genotoxicity assessment has found to not 
be affected by the TU administration. The same results has been assessed also by of Clothier et 
al., (2010). In agreement with former studies, no adverse effects were observed in all the animals 
after both IV and SC administration in the present research.  
Relating to the HPLC-FL study, although the chromatographic conditions are suitable for the 
determination of the IS, the same conditions were not suitable for the determination of the analyte 
TU. All these analytical conditions did not show a right compromise especially in terms of 
sensitivity (LOQ 100 µg/mL) of the instrument for the determination of TU after derivatization 
method in plasma samples. Finally, the derivatization reaction did not show to be repeatable 
between TU concentrations, presenting a high variability between samples.  
Concerning the HPLC/MS-MS, the liquid/liquid extraction provides a selective and accurate 
analysis of TU without the need for expensive clean-up steps. It presents a simple and more rapid 
extraction method compared to the common SPE method (Gáler et al. 2004; Toutain et al., 2017) 
with an optimal recovery (about 90%) of the analyte. 
Relating to the PK study performed in the present research, the pharmacokinetics reported in the 
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goats using the LC-MS/MS, an accurate and sensitive method characterized by a lower LOQ (5 
ng/mL) compared to the microbiological assay performed by Amer et al., (2012). The PK 
parameters showed after IV and SC administration at the dose of 2.5 mg/kg b.w. demonstrated 
similar variabilities to those reported in other studies performed in goats (Amer et al., 2012, Young 
et al., 2011, Clothier et al., 2011), but also reported in cattle (Gáler et al. 2004; Nowakowski et 
al., 2004) and swine (Benchaoui et al., 2004). This can be due to the different animal breed used 
in the studies and the different analytical method performed to determined TU concentration in 
plasma. The pharmacokinetics of a single IV administration of TU in lactating goats during non-
pregnant condition were similar to those in lactating conditions. These similarities are in agreement 
with data observed in other different animal species and different route of administrations (Amer 
et al., 2012). The SC route was chosen for the present study because it is considered the most 
relevant route for the administration of TU in different animal species.  
Following the single SC injection of TU in lactating goats during non-pregnant period, TU was 
rapidly absorbed. Low plasma concentrations of TU were obtained following SC injection, with 
calculated mean Cmax of 520±75 ng/mL at Tmax of 0.63 h. For comparison, a mean Cmax value of 
633ng/mL was obtained at 0.4 h following SC injection in meat goats (Young et al., 2011). 
Mean Cmax values of 987 ng/mL and 1185 ng/mL were obtained following SC injection in 
juvenile and market-age goats, respectively (Clothier et al., 2011), and mean Cmax value of 500 
ng/mL at 1.8 h was observed in cattle following SC injection (Nowakowski et al., 2004).  
In the present study a high Vss after IV injection was found (Vss, 10692±2192 mL/kg). Similarly 
high values for Vss have been reported for TU in lactating goats (16000 mL/kg; Amer et al., 
2012) determined with a microbiological assay, but also in cattle (1110 mL/kg; Nowakowski et 
al., 2004), foals (12700-18200 mL/kg; Scheuch et al., 2007; Schock, 2008) and pigs (13200 
mL/kg; Benchaoui et al., 2004). The basic nature, limited degree of ionization and lipophilicity 
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extensive drug penetration into tissues and fluids, and result in large volumes of distribution and 
higher milk concentrations than plasma concentrations.  
The bioavailability of TU in lactating goats calculated in the present study after SC injection 
resulted almost complete (104%). This is in agreement with the high bioavailability reported in 
cattle (>90%) after SC injection (Nowakowski et al., 2004).  
Moreover, TU showed a low mean plasma clearance (CL) of 136 mL/kg/h after IV injection and 
127 mL/kg/h after SC injection in lactating goats. In order to compare, TU clearance was 126 
mL/kg/h in lactating goats after IV injection (Amer et al., 2012). A value of 208 mL/kg/h was 
observed in meat goats after SC administration (Young et al., 2011). Finally, 250 and 320 
mL/kg/h were found after SC route in juvenile and marked-age goats, respectively (Clothier et 
al., 2011), while after IV injection, values of 181 mL/kg/h were observed in pigs (Benchaoui et 
al., 2004) and 181 mL/kg/h in cattle (Nowakowski et al., 2004).  
TU was slowly eliminated in lactating goats after IV and SC injection with long elimination half 
time (about 58 h for both the administration). For this reason, it was preferable to collect plasma 
samples for longer than the approximate 2 half-lives of data (up to 240 h).  
The mean area under the plasma concentration–time curve from time 0 to infinity (AUC0-∞) of 
TU in lactating goats was 18757 h*ng/mL after IV injection and 19684 h*ng/mL after SC 
injection. Similar mean values of AUC0-∞ have been reported for IV injection in a study on 
lactating goats (25900 h*ng/mL; Amer et al., 2012). Slightly lower mean values of AUC0-∞ 
have been reported in meat goats (12500 h*ng/mL; Young et al., 2011) and in cattle (13500 
h*ng/mL) after SC injection (Nowakowski et al., 2004). On the other hand, all these data were in 
disagreement with the AUC0-∞ values reported by Clothier et al., (2011) (10266 and 8529 
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Concerning the concentration of TU in milk, the high penetration of the drug into milk is due, in 
part, to its basic nature (high pKa), relative to the pH of milk (6.6–6.8). The limit of detection of 
TU in bovine milk determined by Juan et al., (2010) was 10 ng/mL when it was analysed using 
LC-MS/MS, which provides the most sensitive analytical method for quantification of TU in 
milk. In the present study, due to the technical problems, it was not possible to determine an 
analytical method for the determination of the marker residue CP-60,300 of TU in milk. Future 
studies have been planned to develop a more rapid, sensitive and reproducible new analytical 
method for the determination and quantification of TU in milk goats.  
In conclusion, TU may be effective in the treatment of respiratory disease in goats. However, in 
Europe TU administration is not permitted in animals where the milk will be consumed by 
humans (Juan et al., 2010). Further studies are needed to determined a suitable withdrawal times 
required for milk intended for human consumption when TU is administered in “off-label” 
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5. Pharmacokinetics of tapentadol in laying hens and its residues in eggs after 
multiple oral dose administration. 
 
In the last decades, the modernization of food animal husbandry is growing in correlation with the 
growing demand of food from the population. On the other hand, consumers are more interested 
to the suffering of farm animals caused by the routine husbandry procedures (De Vito, 2015; 
Bomzon, 2011; Giorgi et al., 2016). In 2012 of the conventional “battery” cages for laying hens 
were banned from Europe forcing a change towards the use of non-cage and furnished cage 
systems to allow more freedom of movement for these animal species. Surprisingly, the new 
consequence of this change was an increasing in keel fractures of 36% in laying hens with 
furnished cages and 86% with free- range system (Nasr et al., 2012a). 
Different studies have reported that the mammal’s acute pain coming to the bone fractures is 
obtained for an activation of mechanosensitive nociceptors in the periosteum. Although no 
information about the innervation of the keel bone in birds are available in literature, some 
physiological conditions and fracture healing similarities between mammals and birds suggest that 
sensory afferent fibres may densely innerve the keel bone (Nasr et al., 2012a). Some studies in 
literature reported that birds with fractures took longer to reach food in runway tests and took four 
times longer to fly down from a perch to obtain food, compared with healthy hens. Laying hens 
took longer time to complete the landing, flying and walkway tests than healthy hens. Finally, pain 
has been reported to reduce egg production with lower egg quality score (Nasr et al., 2012a; Nasr 
et al., 2012b; Nasr et al., 2015). 
The use of pain relief drugs might be one of the measures to improve animal welfare and pain 
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Vito, 2015; Goetting el al., 2011). Mobility can be partially improved by the administration of 
morphine and butorphanol. However, opioids have complex effects on mood (sedation) and reward 
systems (Nasr et al., 2013). On the contrary, carprofen, flunixin, meloxicam and ketoprofen, drugs 
belongs to the non-steroidal anti-inflammatory drugs class, can modulate the behaviour of birds 
(Nasr et al., 2015). 
Further considerations are the risks to human health posed by veterinary drug residues contained 
in food derivatives, including direct toxic effects and allergic reactions. Indeed, it has been reported 
that drug residues in eggs produced by laying hens can arise when the animals are mistakenly 
given medicated or contaminated feed, or when drugs are administered off-label (Goetting el al., 
2011).  
Tapentadol (TAP), is a new opioid with a unique centrally acting analgesic effect. Due to its 
innovative mechanisms of action, TAP is likely to produce fewer and shorter opioid-related side 
effects than classical MOR agonists while still retaining a good efficacy. These features make TAP 
an attractive prospective drug for use in food producin animals (Giorgi, 2012). 
 
5.1 Aim of the study 
The aim of the present study was to: 
-Evaluate the pharmacokinetics of TAP in laying hens after intravenous and oral administration at 
the dose of 1 and 5 mg/kg respectively. 
-To quantify the concentrations of TAP residues in eggs (yolk and albumen) after multiple oral 
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5.2 Materials and methods 
5.2.1 Chemicals, reagents and solution. 
The pure powder purity (>99.8%) of TAP hydrochloride was provided by Bepharm (Shanghai, 
China). The internal standard (IS), the metabolite of tramadol (M1), had a purity >99.8% and was 
provided  by LCG Promochem (Milan, Italy ).  
TAP and IS singular stock solutions in MeOH were diluted to prepare a 6-point calibration curve 
at the following concentrations 5, 1, 0.500, 0.250, 0.100, and 0.050 μg/mL, of TAP in plasma, yolk 
and albumen, respectively. The analyte was stable for at least 20 weeks if stored at 4° C. 
5.2.2 Animal experiment 
The animal experiment was performed at the University of Pisa, Department of Veterinary 
Sciences. 
Twenty healthy Livorno breed laying hens, 38 weeks old, with an average weight of 1.9 ± 0.2 kg 
according to the European Poultry Standards, were supplied by a local organic farm. The birds 
were checked by a veterinarian who certified the good health status, and the absence of drug 
treatments. The study protocol was approved by the University of Pisa’s ethics committee for 
animal welfare (CEASA) and transmitted to the Italian Ministry of Health (19994 2015)  
Animals were acclimated for a 2-week period prior to beginning the study. During this period, 
laying hens were housed in an indoor area all together on the floor. Regular veterinary checks, 
based on daily physical examination through observation of behaviour and appetite, assessed that 
animals were in good health. Animals were casually distributed into 3 groups (20 slips of paper 
marked with the numbers 1 to 20 selected blinded from a box). Groups A and B with 6 subjects 
and group C with 8 subjects. A ring with an identification code was applied to the right leg of each 
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was provided ad libitum. Standard management practices were followed to keep animals free from 
stress.  
The study was conducted in two phases. During the first phase animals in groups A (n=6) and B 
(n=6) received TAP according to a randomized, parallel study design. After overnight fasting, 
group A received TAP (5 mg/kg) orally by a capsule directly into the chickens' crop. The doses 
were prepared by weighing and partitioning the pure TAP. Group B received the drug 
intravenously through the vein of the right wing using a 2.5 mL syringe and 26- gauge needle. The 
injectable TAP solution was freshly prepared by dissolving pure TAP hydrochloride powder in 
saline to produce 1 mg/mL solution, which were then passed through a 0.45-μm filter, maintaining 
sterile conditions. Blood samples (0.5 mL) were collected in groups A and B at assigned times (15 
min, 1, 2, 4, 6, 8, 10 and 24 h for group A and 5, 30 min, 1, 2, 4, 6, 8, 10 and 24 h for group B) 
using an IV catheter (Venflon 24Gx25mm) fixed into the left wing vein. After centrifugation at 
400xg for 10 min plasma samples were separated for PK analysis, and stored at -20 °C until use 
within 30 days from collection. During the second phase of the study, animals in group C (n=8) 
received TAP orally in multiple doses of 5 mg/kg for 5 days. Eggs were collected every day for 
30 days from the beginning of the study. Yolk and albumen were divided for each egg and stored 
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Figure 24. Animal experiments 
 
5.2.3 Analytical method 
The analytical method was performed at the University of Pisa, Department of Veterinary 
Sciences. 
5.2.3.1 Instrumentation and chromatographic conditions 
The HPLC method with fluorescence detector was based on a previously published technique 
(Giorgi et al., 2012a) with slight modifications. The limits of quantification and detection were 10 
and 3 ng/mL, respectively. The analytical method was re-validated for laying hen plasma samples. 
The accuracy was lower than 6.8%, while intra-and inter-day repeatability was measured lower 
than 9.1%. Emission and excitation wavelengths were set at 298 nm and 273 nm, respectively. The 
chromatographic separation assay was performed with a Luna C18 analytical column (150 x 4.6 
mm inner diameter, 3-μm particle size, Phenomenex) maintained at 25° C. The mobile phase 
consisted of 0.2% acetic acid solution (A): ACN (B) at a flow rate of 1 mL/min. The linear gradient 
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from 40% B - 60% A to 5% B - 95% A (20 to 20.1 min) and 5% B - 95% A isocratically (20.1 to 
22 min). 
5.2.3.2 Sample preparation 
The procedure of TAP extraction from plasma was based on that previously reported by Giorgi et 
al. (2012a) with slight modifications. 
Concerning the preparation of plasma samples, in a 1.5-mL polypropylene snap cap tube 
containing 0.2 mL of plasma, 0.1 mL of IS solution (0.1 μg/mL) and 0.2 mL (0.2 M) borate buffer 
(borax solution at pH 9.3) were added. Samples were vortex and added with 0.4 mL of extraction 
solvent CH2Cl2 : Et2O (3:7 v/v). After vortexing, samples were shaken and then centrifuged for 10 
min at 15,000g and the organic layer (0.15 mL) was transferred into a clean 1.5-mL polypropylene 
snap cap conical tube. A volume of 0.2 mL of back-extraction solvent ACN 0.05 M : HCl (1:1 
v/v) was added to the samples. The aqueous phase obtained after centrifugation (50 μL) was 
injected onto the HPLC-FL system.  
About the preparation of yolk samples, a quantity of 1 g (each sample) was diluted with 1 mL of 
borate buffer (0.2 M) and was added 100 μL of IS solution (0.1 μg/mL). After vortexing, 1 mL of 
extraction solvent CH2Cl2:Et2O (3:7 v/v) was added. The organic layer (0.8 mL) obtained from 
centrifugation was then transferred into a clean 1.5-mL polypropylene snap cap conical tube. Four 
hundred L of back-extraction solvent 0.05 M HCl : ACN (1:1 v/v) was added to the tube. Fifty 
μL of the aqueous lower layer was injected onto the HPLC-FL system.  
Finally, for the preparation of albumen samples 1 mL of sample was diluted with 1 mL of borate 
buffer (0.2 M). One mL of the final solution was placed in a 2 mL polypropylene snap cap conical 
tube, added to 100 μL of IS solution (0.1 μg/mL) and vortexed for 30 s After vortexing-mixing, 
400 μL of extraction solvent (CH2Cl2 : Et2O (3: 7 v/v) was added. Then the tube was placed in a 
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(0.15 mL) was transferred into a conical tube, 0.4 mL of back-extraction solvent 0.05 M HCl : 
ACN (1:1 v/v) was added and after centrifugation the aqueous layer (50 μL) was injected onto the 
HPLC-FL system.  
5.2.3.3 Sample quantification 
Standard curves were constructed with standard TAP concentrations vs ratio of TAP/internal 
standard peak areas. Linearity of the regression curve in the range of 50-5000 ng/mL for plasma 
yolk and albumen were assessed on the basis of the residual plot, the fit test and the back 
calculation. Limit of quantitation (LOQ) was determined as signal-to-noise ratios of 10, while the 
limit of detection (LOD) as the signal-to-noise ratios of 3. The HPLC-FL method for plasma and 
eggs were validated by examining the within-run precision calculated from similar responses for 
six repeats of 3 control samples (50, 500, and 1000 ng/mL) in one run. Moreover, the HPLC-FL 
method was validated by examining the between-run precision determined by comparing the 
calculated response of the low (50 ng/mL), middle (500 ng/mL), and high (1000 ng/mL) control 
samples over three consecutive daily runs (total of 6 runs). The assay accuracy for within-run and 
between-runs was established by determining the ratio of calculated response to expected response 
for low (50 ng/mL), middle (500 ng/mL), and high (1000 ng/mL) control samples over 6 runs. 
The efficiency of extraction method was evaluated by comparing the response (in area) of high, 
middle, low standards and the IS, spiked into blank plasma, to the response of equivalent extracted 
standards. 
5.2.4 Pharmacokinetic analysis 
Pharmacokinetic parameters for intravenous and oral administration were determined individually 
as a non-compartmental model using WinNonlin 5.3.1 software (Pharsight).  
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Eq. 10     F = 
𝐴𝑈𝐶 (PO) x dose IV
𝐴𝑈𝐶 (𝐼𝑉) x dose PO
 
 
5.2.5 Statistical Analysis  
The Kolmogorov-Smirnov test was applied to verify data distribution. Statistical comparison of 
PK parameters was determined with Student’s t-test and performed by Graph Pad In Stat (Graph 
Pad Software). The PK parameters and TAP residues in yolk and albumen are presented as means 
± SD. In all experiments, differences were considered significant if P< 0.05. 
 
5.3 Results 
5.3.1 Pharmacokinetics of Tapentadol 
No visible adverse effects were observed during the experiment. Following IV and PO 
administrations of TAP at 1 and 5 mg/kg respectively, the plasma concentration vs time curves are 
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Figure 25. Mean plasma concentration vs time curve of tapendadol after IV (——) and PO (—
●—) administrations at 1 and 5 mg/kg respectively in laying hens (n=12). Bars represent the SD. 
The horizontal dotted and dashed line shows the minimal effective concentration (MEC; 148 
ng/mL) reported for humans and its intercepts with the concentration vs time curves reported in 
laying hens 
 
TAP plasma concentrations after IV and PO administrations were detectable up to 4 h. Only the 
IV administration reached concentrations higher than the minimal effective concentration (MEC 
148 mg/mL) reported for human and this was only for the first 1 h (Tzschentke et al., 2007). 
Pharmacokinetic parameters of TAP after IV administration are presented in Table 14. After PO 
administration, TAP demonstrated fast absorption and elimination and plasma concentrations that 
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Table 14. Pharmacokinetic parameters of TAP after IV administration at 1 mg/kg in laying hens 
(n=6). 
        IV 
Parameters   Units   Mean   SD 
r2       0.96 ± 0.05 
λz   1/h   0.76 ± 0.11 
HLλz   h   0.94 ± 0.15 
C0   ng/mL   292 ± 102 
AUClast   h*ng/mL   369 ± 110 
AUC0-∞   h*ng/mL   389 ± 109 
Vss   mL/kg   3299 ± 1136 
V/F   mL/kg   3764 ± 1322 
Cl/F   mL/h/kg   2749 ± 796 
AUMClast   h*h*ng/mL   355 ± 129 
MRTlast   h   0.96 ± 0.15 
r2, correlation between observed/predicted points; λZ, first-order rate constant; HLλZ, half-life of the terminal 
portion of the curve; C0, concentration at time 0; AUClast, area under the curve from 0 to the last; AUC0-∞, 
area under the curve from 0 to ∞; V/F, volume of distribution during the elimination phase; CL/F, body 
clearance during the elimination phase; AUMClast, area under the first moment curve from 0 to the last; 
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5.3.2 Disposition of TAP in eggs (albumen and yolk) 
TAP concentrations following multiple PO doses at 5 mg/kg for 5 days were quantifiable in the 
incurred albumen and yolk up to 7 and 12 days respectively (Figure 26; Figure 27). Figure 26 
showed low (near the LOD) and not significantly different daily TAP concentrations in albumen 
up to 7 days after the first administration. Figure 27 showed a higher concentration of TAP in yolk 
than in albumen. The concentrations of TAP in yolk decreased from the sixth day up to twelfth 
day. At that time, the concentration was very close to the LOD of the instrument. 
 
 
Figure 25. Disposition of TAP in albumen after PO multiple dose (5 days) at 5 mg/kg in laying 
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Figure 26. Disposition of TAP in albumen after PO multiple dose (5 days) at 5 mg/kg in laying 
hens (n=8). Bars represent the SD 
 
5.4 Discussion and conclusion 
The present study represents the first pharmacokinetics of TAP in laying hens, although studies in 
different animal species have recently been published (Giorgi et al., 2012b; Giorgi et al., 2013; 
Lee et al., 2013; Lavy et al., 2014; Giorgi et al., 2015). 
To the best of the authors’ knowledge, there are no published reports of the TAP pharmacokinetics 
in laying hens thus far. Drug dosing schedule for the laying hens was extrapolated from studies on 
other animal species (Giorgi et al., 2012b; Giorgi et al., 2013; Lee et al., 2013; Lavy et al., 2014; 
Giorgi et al., 2015). The orally administered dose (5 mg/kg) in laying hens, appears high if 
compared with previous studies. In a clinical study (Pasero, 2011), the oral dose administered in 
humans was 200 mg/subject; this showed a low bioavailability (30%). Another study in dogs 
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(200 mg/dog). Due to this likely low bioavailability, the authors decided to double the oral dose 
for administration to laying hens. 
In contrast, to preserve the heath of the animals, in the present study a lower IV dose (1 mg/kg 
b.w.) was chosen to avoid the presence of some slight and transitory side effects observed in 
literature after IV administration in other animal species (Giorgi et al., 2012b; Lavy et al., 2014).  
In humans, the MEC is equivalent to 148 ng/mL (Tzschentke et al., 2007). If the human MEC also 
applies to laying hens, the plasma drug concentration reported in the present study, after IV 
administration at the dose of 1 mg/kg, exceeded this value for not more than 1 h. However, 
extrapolation of the humans MEC value for laying hens might not be prudent and attention should 
be used (Giorgi and Yun, 2012). It is also recognized that there could be some discrepancy between 
the actual effect at the receptor level and plasma concentration of the drug (Toutain & Lees, 2004). 
Indeed, recently the administration of TAP in rabbits was reported to be effective for at least 10 h 
after a 5 mg/kg IV administration, although TAP concentrations were below the human MEC after 
2 h. This effect suggested to the authors the possible long lasting effect of TAP in rabbits (Giorgi 
et al., 2013).  
The low plasma concentrations after oral dosing in the current study, triggered by the low F% (not 
calculated) prevented a complete description of the drug concentration vs time curves (especially 
in the terminal phase). This is in agreement with the low value of F% found in dogs (Giorgi et al., 
2012b). Glucuronidation is the main metabolic pathway for TAP in humans, as 83% of an oral 
dose of TAP is converted into and excreted as inactive glucuronated metabolite from the UDP-
glucuronyl transferases (Terlinden et al., 2007). Humans and dogs are reported to have some 
similarities in UDP-glucuronyl transferases (Soars et al., 2001). However, dogs showed a low PO 
bioavailability (about 4%) of TAP (Giorgi et al., 2012b). On the contrary, cats have very limited 
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TAP reported in the literature (Lee et al., 2013). Unfortunately, there is little information in the 
published literature about glucoronidation and UDP-glucuronyl transferase enzymes in laying hens 
and other similar animal species (Bartlet & Kirinya, 1976). These results suggest that, due to its 
low F%, PO administration of TAP could not be generally recommended in laying hens. 
In the present study, the IV administration showed a high inter- and intra-variability in both plasma 
concentrations and pharmacokinetic data. This is in agreement with previous studies on opioids 
(Taylor et al., 2001). The pharmacokinetic analysis showed that TAP, when administered by IV 
route in laying hens at the dose of 1 mg/kg, was rapidly and widely distributed to tissues with a 
distribution volume (Vd) of 3765 mL/kg. Clearance and half-life (T1/2 λz) were 2749 mL/h/kg 
and 0.94 h, respectively. If Cl and Vd are normalized for the dose, they are similar to those 
observed in dogs but different to those in cats, goats, turtles and rabbits. These results can reflect 
the wide differences in metabolism of diverse animal species (Giorgi et al., 2013; Lee at al., 2013; 
Lavy et al., 2014; Giorgi et al., 2015). 
A few drugs are approved and labelled for laying hens and eggs because of their residues. Eggs 
present three components: yolk, albumen and shell. The yolk presents a lipophilic site for drug 
accumulation with the longest development time. The albumen is laid down over a period of 2-3 
h and can also be an accumulation site. Many drugs residue preferentially in yolk and albumen 
rather than in shell. Because of the protracted nature of egg development, many weeks may be 
required following treatment or exposure before eggs are free of drug residues (Goetting et al., 
2011). This is in agreement with the results of the present study where the TAP concentration in 
yolk was shown to be higher than in albumen. Moreover, TAP concentration in yolk was detectable 
for a longer time (12 days) than in albumen (7 days). After that time the TAP concentration was 
below the LOD (3 ng/mL) of the instrument. There are no official MRLs of TAP in eggs produced 
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In conclusion, this is the first pharmacokinetic study on the novel atypical opioid TAP in laying 
hens. Further studies are necessary to assess the F% of TAP and its analgesic efficacy in this animal 
species. However, due to the low bioavailability, this drug doesn’t seem suitable for pain treatment 
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6. Pharmacokinetics of meloxicam in lactating goats (Capra hircus) and its 
quantification in milk after a single intravenous and intramuscular injection. 
 
6.1 Introduction 
Production of animal food derivatives safe for the human consumption is one of the most important 
issues of this century. On the other hand, society has become progressively more conscious about 
potential suffering in production animals and aware of the necessity of new pain therapies for its 
prevention and treatment (Giorgi et al., 2016). Therefore, there is a demand for novel therapies to 
relieve pain in food producing animals (De Vito, 2015). 
Nowadays, though domestic goats are present as a worldwide population in numbers large enough 
to confer a status of major species, these animals are still considered as a minor species by the 
regulatory agencies in Europe and the USA (Toutain et al., 2010). Due to the lower number of 
goats compared to the other livestock species their health issues cannot be addressed with EMA 
or FDA-approved medications. Consequently, many drugs are administered to goats in an extra-
label manner with no scientific information on drug behaviour, potential toxicity, and adequate 
withdrawal periods for drug removal from products marketed for human consumption (Clothier, 
2010). 
Meloxicam (MEL) is a potent anti-inflammatory drug belonging to enolic acid group of the oxicam 
class, having analgesic and antipyretic properties. MEL, if compared to the common non-steroidal 
anti-inflammatory drugs (NSAIDs), has been shown to be more preferential in inhibiting COX-2 
(12 times more selective as a COX-2 inhibitor in the dog) than COX-1 isoenzyme, preventing the 
occurrence of inflammation by the inhibition of prostaglandin production that sensitize the afferent 




Dr. De Vito Virginia 
“Pharmacokinetic studies of “off-label” drugs in food producing animals. Quantification of drug residues in different organic matrices.” 
Tesi di Dottorato in Scienza Veterinarie, Qualità e Sicurezza Alimentare, Università degli studi di Sassari 
in a lower ulcerogenic side effect and gastrointestinal irritation (Wani et al., 2013; Wani et al., 
2014). 
The pharmacokinetic profile of MEL shows good absorption, longer elimination half-life and high 
extravascular bioavailability in different animal species: dogs (Hare et al., 2012; Montoya et al., 
2004; Busch et al., 1998), cats (Lehr et al., 2010; Giraudel et al., 2005), horses (Lees et al., 1991; 
Toutain & Cester, 2004; Toutain et al., 2004; Burns et al., 2010), rabbits (Turner et al., 2006; 
Carpenter et al., 2009), turtles (Di Salvo et al., 2015), green iguanas (Divers et al., 2010), piglets 
(Alassane et al., 2010; Fosse & Spadavecchia, 2011), cattle (Johnn et al., 2011; Coetzee et al., 
2007; Coetzee et al., 2012), camels (Wasfi et al., 2012) and Ilamas (Amanda et al., 2012). Little 
and conflicting information only is available for small ruminants (Shukla et al., 2007; Ingvast-
Larssom et al., 2010; Wani et al., 2013; Wani et al., 2014). 
 
6.2 Aim of the study 
The aim of the present study was two-fold:  
-Determine the pharmacokinetics of MEL after intravenous (IV) and intramuscular (IM) route of 
administrations at the dose of 0.5 mg/kg b.w. in goats  
-Quantify MEL residues in milk.  
 
6.3 Materials and methods 
6.3.1 Chemicals and reagents 
The pure powder (purity >99.8%) of MEL was provided by LCG Promochem (Milan, Italy). The 
pure powder of piroxicam, the internal standard (IS), (> 99.8%) was provided by LCG Promochem 
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6.3.2 Animal experiment 
The animal experiment was approved by the animal welfare ethics committee of the University of 
Lublin (authorization 43/2017) and carried out in accordance with the European law 
(2010/63/UE). 
Six healthy 1-2 year old mixed breed lactating goats, with an average weight of 55 kg were used 
in the study. Goats were examined to be clinically healthy based on blood analysis and absence of 
any apparent clinical signs before the commencement of the study. All the animals were housed 
in an animal shed and were acclimatized to the new environment for 7 days. The animals were fed 
twice a day and water was provide ad libitum. The feed was withheld the night preceding the day 
of the experiment until 6 h post drug administration. 
Goats were randomly assigned to 2 treatment groups (6 slips of paper marked with the numbers 
from 1 to 6 in a box), using an open, single-dose, two-treatment, two-phase, unpaired, cross-over 
design (2x2 Latin square). On the day of experiment, the goats’ necks were shaved and a local 
anaesthetic (Emla®, ointment, lidocaine 25 mg⁄g, prilocaine 25 mg⁄g; AstraZeneca) was spread on 
the skin above the jugular veins. Two catheters were placed in the jugular veins, one only in the 
IV injection group (right) and the other for blood sampling (left) in both groups. Group A (n=3) 
received a single dose of MEL (Metacam® solution for injection 20 mg/mL, Boehringer Ingelheim) 
at 0.5 mg/kg b.w. intravenously. Group B (n=3) received the same dose of MEL by an 
intramuscular injection in to the right gluteal muscle. A wash-out period of 3 weeks was observed 
between phases, the groups were rotated and the experiment was repeated. Blood samples (10 mL) 
were collected immediately before and at 5, 15, 30 and 45 min, 1, 1.5, 2, 4, 6, 8, 10, 24, 36, 48, 
60, 72, 96, 120, 144, and 168 h after administration of the drug. Goats were totally milked from 
both udders immediately before and after the administration of the drug at 10, 24, 36, 48, 60, 72, 
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were stored at -20 °C until use within 30 days from collection. A licensed veterinarian (BLW) 
evaluated the presence of likely adverse effects from the time of drug administration up to 7 days 
(Figure 27). 
 
Figure 27. Animal experiments 
 
6.3.3 Analytical method 
6.3.3.1 Instrumentation and chromatographic conditions  
The HPLC method was based on a previously published technique (Kimble et al., 2013) with slight 
modifications. The chromatographic separation assay was performed with a Gemini C18 analytical 
column (250 x 4.6 mm inner diameter, 5-μm particle size, Phenomenex) maintained at 25° C. The 
mobile phase consisted of ACN (A): 0.05 M phosphate buffer pH 3.2 (B) at an isocratic flow rate 
of 1 mL/min. The wavelength was set at 365 nm. The analytical method was re-validated for 
lactating goats’ plasma and milk samples according to the EMA guidelines (EMA, 2012) by 
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samples (50, 500, and 1000 ng/mL) in one run. The between-run precision was determined by 
comparing the calculated response of the low (50 ng/mL), middle (500 ng/mL), and high (1000 
ng/mL) control samples over three consecutive daily runs (total of 6 runs). The assay accuracy for 
within-run and between-runs was established by determining the ratio of calculated response to 
expected response for low (50 ng/mL), middle (500 ng/mL), and high (1000 ng/mL) control 
samples over 6 runs. Limit of quantitation (LOQ) was determined as signal-to-noise ratios of 10, 
and the limit of detection (LOD) as the signal-to-noise ratios of 3.  
6.3.3.2 Sample quantification 
MEL and IS singular stock solutions in ACN were diluted to prepare a 7-point calibration curve 
at the following concentrations 2.5, 1, 0.5, 0.1, 0.05, 0.025 and 0.015 µg/mL of MEL in plasma 
and milk matrices. Standard curves were constructed with standard MEL concentrations vs ratio 
of MEL/internal standard peak areas. The analyte was stable for at least 20 weeks if stored at 4° 
C. Linearity of the regression curve for plasma and milk were assessed on the basis of the residual 
plot, the fit test and the back calculation. The efficiency of extraction method was evaluated by 
comparing the response (in area) of high, middle, low standards and the IS, spiked into blank 
plasma or milk, to the response of equivalent standards. 
6.3.3.3 Plasma sample preparation  
In a 15 mL polypropylene snap cap tube containing 500 µL of plasma, a volume of 100 μL of IS 
solution (10 μg/mL) was added. After vortexing, 2.2 mL of ACN was added to the samples and 
vortexed again. Finally, 0.1 gr of NaCl was added for the optimal separation of the organic and 
aqueous phases. After vortexing, samples were shaken for 10 min at 60 osc/min and then 
centrifuged for 10 min at 4500 g and the organic layer (2 mL) was transferred into a clean 5 mL 
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nitrogen at 40 °C and reconstituted with 200 µL of the mobile phase. Fifty µL of this latter solution 
was injected onto the HPLC-DAD system. 
6.3.3.4 Milk sample preparation  
Milk samples (500 µL each sample) were added to 100 μL of IS solution (10 μg/mL). After 
vortexing, 2.2 mL of ACN was added to the samples and vortexed again. Finally 0.1 gr of NaCl 
was added to optimize the separation of the organic and aqueous phases. After vortexing, samples 
were shaken for 10 min at 60 osc/min and then centrifuged for 10 min at 4500 g and the organic 
layer (2 mL) was transferred into a clean 5 mL polypropylene snap cap conical tube. The organic 
phase was evaporated under a gentle stream of nitrogen at 40 °C and reconstituted with 200 µL of 
the mobile phase. Fifty µL of this latter solution was injected onto the HPLC-DAD system. 
6.3.4 Pharmacokinetic analysis 
MEL plasma concentration vs time curves were modelled for each subject using compartmental 
analysis (Gibaldi & Perrier, 1982). Comparison between competing models was made using the 
goodness of fit, Akaike’s information criterion, Schwarz Bayesian information criterion, the sum 
of square of the residuals and the visual inspection of the curves. The pharmacokinetic calculations 
were carried out using WinNonlin v 5.3.1 (Pharsight, La Lolla, CA, USA). The elimination half-
life (Beta_HL) was evaluated by ln2/z while the elimination rate constant was estimated by semi-
log lineal regression of the terminal slope. Area under the plasma vs time curve (AUC) was 
calculated from 0 to the last quantifiable concentration using a linear trapezoidal method. For 
intravenous administration, plasma clearance (Cl) and the total volume of distribution at steady-
state (Vss) were determined. 
The IM bioavailability (F%) was calculated as (Eq. 11): 
Eq. 11     F= 
AUC (IM)
AUC (IV)
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Afterwards, basing on the pharmacokinetic data, a WinNonlin 5.3.1 simulation was performed. It 
was executed to establish if multiple administrations of MEL to goats IM at 0.5 mg/kg once a day 
would achieve the values of average therapeutic plasma concentration (MEC) reported in literature 
for cats (347 ng/mL), dogs (833 ng/mL) and horses (735 ng/mL). These latter values were 
calculated from approved maintenance dose and reported clearance values (Toutain et al., 2004; 
Toutain & Lassourd, 2002). In agreement with the MEC values of MEL reported above, other 
PK/PD studies performed in cats and horses showed EC50 values of about 900 ng/mL and 195 
ng/mL in horse and cat, respectively (Toutain & Cester, 2004; Giraudel et al., 2005). 
6.3.5 Statistical Analysis  
The Kolmogorov-Smirnov test was applied to verify data distribution. Statistical comparison of 
PK parameters was determined with Student’s t-test and performed by Graph Pad In Stat (Graph 
Pad Software). The PK parameters and MEL residues in milk are presented as means ± SD. In all 
experiments, differences were considered significant if p< 0.05. 
 
6.4 Results 
The HPLC method was revalidated using plasma and milk from control goats. Briefly, MEL was 
linear in the range of 15–2500 ng/mL for both plasma and milk. LOD was 5 ng/mL and LOQ was 
15 ng/mL for both plasma and milk. When samples exceeded the upper limit of the range, they 
were re-analysed after appropriate dilution. The recoveries obtained were 89.3 ± 5.8% and 85.7 ± 
3.2% for plasma and milk samples, respectively. The intra-day repeatability for plasma and milk 
was lower than 4.6% and 5.1% respectively, whereas accuracy was lower than 6.2% and 6.9%, 
respectively. 
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6.4.1 Pharmacokinetics of meloxicam 
Following IV and IM administrations of MEL at the dose of 0.5 mg/kg b.w, the plasma 
concentration vs time curves are illustrated in Figure 28. MEL plasma concentrations after IV and 
IM administrations were detectable up to 96 h. At 120 h, the drug concentrations dropped below 
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Figure 28. Mean plasma concentration vs time curve of MEL after IV (——) and IM (—●—) 
administrations at 0.5 mg/kg in lactating goats (n=6). Bars represent the SD. 
 
Pharmacokinetic parameters of MEL after IV injection were best fitted with the bi-compartmental 
model, while a mono-compartmental model best fitted plasma concentration after IM injection. 
MEL elimination phase from plasma was similar in both the administration groups. These 
similarities between routes of administration were proved by the pharmacokinetic parameters 
shown in Table 15 and 16. No pharmacokinetic parameters were shown to be significantly different 
between routes of administration. The bioavailability (F%) after IM administration was shown to 
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Table 15. Pharmacokinetic parameters of MEL after IV administration at 0.5 mg/kg in lactating 
goats (n=6). 
 
              
 
 
    IV 
 
Parameter   Units   Mean   SD 
 
 
AUC   h*ng/mL   26499 ± 4233 
 
 
K10   1/h   0.12 ± 0.03 
 
 
K12   1/h   0.64 ± 0.38 
 
 
K21   1/h   1.13 ± 0.71 
 
 
K10_HL   h   6.07 ± 1.18 
 
 
Alpha   1/h   1.82 ± 1.09 
 
 
Beta   1/h   0.07 ± 0.02 
 
 
Alpha_HL   h   0.53 ± 0.35 
 
 
Beta_HL   h   9.96 ± 2.51 
 
 
A   ng/mL   1223 ± 153.71 
 
 
B   ng/mL   1840 ± 357.69 
 
 
AUMC   h*h*ng/mL   374373 ± 120223 
 
 
MRT   h   13.88 ± 3.36 
 
 
CL   mL/h/kg   19.38 ± 3.86 
 
 
Vss   mL/kg   262.37 ± 50.74 
 
 
V1   mL/kg   165.76 ± 23.06 
 
 
V2   mL/kg   96.61 ± 31.07 
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Table 16. Pharmacokinetic parameters of MEL after IM administration at 0.5 mg/kg in lactating 
goats (n=6). 
                  
            IM     
  Parameter   Units   Mean   SD   
  Tmax   h   3.73 ± 2.08   
  Cmax   ng/mL   1409 ± 40.78   
  AUC   h*ng/mL   28071 ± 7630   
  K01   1/h   1.13 ± 0.86   
  K10   1/h   0.07 ± 0.01   
  K01_HL   h   1.08 ± 0.76   
  K10_HL   h   10.82 ± 2.75   
  CL/F   mL/h/kg   18.77 ± 4.29   
  V/F   mL/kg   280.85 ± 33.50   
  F%       105.93 ± 8.23   
                  
 
The plasma concentration vs time curve of the simulated multiple dose (0.5 mg/kg/day) of MEL 
by IM injection in goats is illustrated in Figure 29. At the steady state, the AUC value was 32593 
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Figure 29. Disposition of TAP in albumen after PO multiple dose (5 days) at 5 mg/kg in laying 
hens (n=8). Bars represent the SD 
 
6.4.2 Disposition of MEL in milk 
MEL concentrations following IV and IM injection at the dose of 0.5 mg/kg b.w. were quantifiable 
in the milk samples up to 60 and 48 h, respectively (Figure 30). The average milk concentration 
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Figure 30. Disposition of TAP in albumen after PO multiple dose (5 days) at 5 mg/kg in laying 
hens (n=8). Bars represent the SD 
 
6.5 Discussion and conclusion 
The primary objective of this study was to determine the pharmacokinetics of MEL in lactating 
goats after IV and IM administrations.  
After IV administration the bi-compartment model provided the best fit of the concentration-time 
data while after IM injection the best fit was provide by the mono-compartment model. This 
difference can be triggered by a common phenomenon and is due to the value of the absorption 
rate constant being similar or lower than the rate constant for the distribution phase. In this study, 
the absorption phase did not appear in the curves and the drug’s disposition performed better with 
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Some information about MEL pharmacokinetics in goats and other small ruminant species are 
present in the literature (Shukla et al., 2007; Ingvast-Larssom et al., 2010; Wani et al., 2013; Wani 
et al., 2014). In the present study, the mean AUC value (26499 ± 4233 ng*h/mL) was similar to 
data reported by Shukla et al., (2007) (19230 ± 2230 ng*h/mL) and Ingvast-Larssom et al., (2010) 
(29738 ± 8576 ng*h/mL). In contrast, this value is in disagreement with data reported by Wani et 
al., (2013), if normalized for the dose (2635 ± µg*h/mL at the dose of 1 mg/kg b.w.). The mean 
half-lives of elimination obtained in the present study (9.96 and 10.82 h) were similar to the values 
reported by Shukla et al., (2007) (7 h), Ingvast-Larssom et al., (2010) (10.9 h) and Wani et al., 
(2013) (8 h). Finally, the mean values of Cl (19.38 ± 3.86 mL/h/kg) and Vss (262.37  ± 50.74 
mL/kg) obtained in the present study were in agreement with data reported by Ingvast-Larssom et 
al., (2010) (Cl 17.9 ± 4.3 mL/h/kg and Vss 245 ± 62 mL/kg) and Wani et al., (2013) (Cl 22 mL/h/kg 
and Vss 276 mL/kg). In contrast, Shukla et al., (2007) reported a similar Vss value (250 mL/kg) 
but different plasma Cl (30 mL/h/kg). These differences could be due to differences in weight 
(Shukla et al., 2007 about 20 kg, Ingvast-Larssom et al., 2010 about 44 kg, present study about 55 
kg), variations in breed used in the diverse studies, and to the different LOQ of the analytical 
techniques (Toutain and Bousquet-Mélou, 2004). 
Concerning the IM route of administration of MEL in goats, few data are reported in the literature. 
A study of Ingvast-Larssom et al., (2010) presented an estimated half life of elimination value of 
14.4 ± 5.2 h obtained in 3 hornless goat kids after IM administration of MEL. This value represents 
an estimation of half life of elimination only, due to the small number of animals used and the 
small number of blood samples collected in that study. A similar mean half life of elimination 
value (10.82 ± 2.75 h) was shown in the present study.  
A dosage regimen of 0.5 mg/kg b.w. once a day by IM administration was simulated. The steady 
state was achieved after the third administration. Based on the assumption that goats have a similar 
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present study were always above the MEC for cats (347 ng/mL). In contrast, the plasma 
concentrations of MEL were above the MEC value reported in dog (833 ng/mL) for 16 out of the 
24 h. It should be keep in mind though that the mean plasma concentration within 24 h (1358 
ng/mL) obtained after the simulation was well above the MEC reported for dogs (833 ng/mL) or 
the EC50 in horse (900 ng/mL). In conclusion, the relatively long half life of elimination, the 
complete F% of the IM injection and the high value of the mean plasma concentration within 24 h 
calculated after simulation, suggests that the drug can be administered once a day by the IM route. 
6.5.1 Disposition of MEL in milk 
Few drugs are approved and labelled for lactating goats because of the likely drug residues in the 
milk. After a single dose of MEL by IV and IM administrations, the drug residues showed similar 
concentrations and a similar trend of elimination. This is in line with the similar trend of 
elimination reported for the plasma and the complete IM F%. Milk samples were collected in the 
present study until 168 h but MEL concentrations could only be quantified until 48h and 60h for 
IM and IV groups, respectively.  
No maximum residual limits established for lactating goats are allowed in milk entering in the 
human food chain. Concerning the approval for use of MEL in bovine, EMEA/MRL/635/99-
FILAL (1999) identified MEL as the marker residue and the ratio to total residues of 0.75 for milk. 
Moreover, in cattle, after a recommended single dose of 0.5 mg/kg b.w. administered by IV or 
subcutaneous injection, the corresponding mean concentrations of MEL for low and high milk 
yields were 347 and 325 ng/mL, respectively. These values decline until the MRLs value (15 
µg/kg) established for cattle is achieved at day 5 after the administration. Assuming the LOQ 15 
ng/mL in the present study as a possible MRLs (Lin et al., 2016), after IV and IM injection milk 
concentrations fell below the LOQ at 72 and 60 h, respectively. The rate of depletion in goat’s 
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metabolism of goats compared with sheep or cattle. This is linked to their respective feeding 
behaviour where goats are natural browsers that can stand on their hind legs or even climb trees. 
They preferably eat leaves, shrubs, flowers and fruits, thus choosing the most nutritious available 
food but also the portions of plants containing many toxic alkaloids that need to be metabolised 
by a hepatic first pass effect. In contrast cattle are a non-selective bulk feeder that graze non 
selective grass generally low in term of alkaloid content (Toutain et al., 2010). 
Further studies are needed however to determine the milk concentrations after multiple 
administrations of MEL at 0.5 mg/kg once a day in a larger number of animals to determine the 
accurate withdrawal time for milk intended for human consumption (EMEA/MRL/635/99-FILAL, 
1999; EMEA/CVMP/473/98-FINAL, 2000). 
In conclusion, IV and IM administration of MEL in lactating goats showed similar 
pharmacokinetic profiles. The dose of 0.5 mg/kg used in the simulation study provided plasma 
concentrations above the MEC determined for other animal species for most of the 24 h. This latter 
value along with the high IM F% and the long half-life of elimination suggested that the drug could 
be administered once a day. The present study showed that MEL concentrations in milk are to 
some extent in agreement with the depletion of MEL in cattle milk. Further studies are required to 
clarify the dose needed to produce effective analgesia and to avoid the risk of milk contamination 
in goats. 
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